{"id": "1adc970c-d433-44d0-aa09-d3834986f7a2", "result": "ENTAILMENT.\n\nThe statement mentions a 13.2% difference between the results from the two primary trial cohorts, which is within the margin of error for the confidence interval provided in the results (87-89% for exemestane and 88-90% for anastrozole). Therefore, the statement entails from the given trial information."}
{"id": "6b9162d0-0816-46d4-81af-c60028dcc63b", "result": "ENTAILMENT.\n\nThe statement mentions that patients with significantly elevated ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or over. This is consistent with the eligibility criteria for the primary trial, which excludes patients with cardiac left ventricular function with resting ejection fraction < 50% (below upper limit of normal), and the eligibility criteria for the secondary trial, which does not have this exclusion criterion and instead focuses on premenopausal women 55 years of age or younger with regular menstrual cycles. Therefore, the statement entails from the given trial information."}
{"id": "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f", "result": "CONTRADICTION.\n\nThe statement suggests that a significant number of participants in both trials suffered from Enterocolitis, but the adverse event tables provided earlier show that there were no cases of Enterocolitis in the primary trial and only one case in the secondary trial. Therefore, the statement contradicts the information provided in the tables."}
{"id": "cc1f712a-2116-4e40-9810-f315e3fa5ff8", "result": "CONTRADICTION.\n\nThe statement suggests that the primary trial does not report the PFS or objective response rate of its patient cohort, but the Results section of the trial provides information on the local control using ipsilateral breast tumor recurrence rates, which is a measure of the treatment's effectiveness in preventing the cancer from coming back in the same breast. This implies that the trial did report on the treatment's effectiveness, which contradicts the statement."}
{"id": "904061c0-14fa-4f13-9118-9a41e24fa8eb", "result": "ENTAILMENT.\n\nThe statement suggests that prior treatment with fulvestrant or a PI3K inhibitor will not prevent a patient from participating in the primary trial, and this is consistent with the eligibility criteria provided. The eligibility criteria state that patients who have received prior treatment with fulvestrant or a PI3K inhibitor are not excluded from participating in the trial. Therefore, the statement entails from the given trial information."}
{"id": "43ee7645-ce1e-42d5-9a74-3e379f6f367b", "result": "CONTRADICTION.\n\nThe statement suggests that only patients with a HER2-positive status can take part in the primary trial, but the eligibility criteria provided earlier mention that patients with unknown HER2 status, and for whom determination of HER2 status is not possible, are eligible for this study. Therefore, the statement contradicts the information provided in the eligibility criteria."}
{"id": "0cef8c8e-7986-46c7-a597-c5733a9899c0", "result": "ENTAILMENT.\n\nThe statement entails from the given trial information. The results section provides the median PFS for both arms of the trial, with the shortest PFS in cohort 1 being 6.8 months and the shortest PFS in cohort 2 being 5.6 months. Therefore, the statement that the shortest PFS in cohort 1 was under 7 months and the shortest PFS in cohort 2 was just over 7 months is true and consistent with the information provided in the trial results."}
{"id": "43ce26e5-03fa-4e9d-b0eb-6ea356295753", "result": "ENTAILMENT.\n\nThe statement entails from the given trial information. Both interventions, HER2+ TC and HER2+ C, consist of 17 cycles, each lasting 3 weeks. The cycles are composed of different drugs and dosages, but both interventions have the same total number of cycles and cycle length. Therefore, the statement is true and consistent with the information provided in the trial's intervention section."}
{"id": "3facad41-0221-42f8-834d-470e65c4aad5", "result": "ENTAILMENT.\n\nThe statement entails from the given trial information. The primary endpoint of the trial is progression-free survival (PFS), which is defined as the length of time during and after the treatment that a patient survives with the disease. The trial is designed to evaluate the safety and efficacy of the Trastuzumab, Bevacizumab, and Docetaxel regimen, and the PFS is used as the outcome measurement to assess the efficacy of the treatment. Therefore, the statement is consistent with the information provided in the trial's results section."}
{"id": "9cbc00e9-3a2d-4471-a93e-72c95132fb6a", "result": "ENTAILMENT.\n\nThe statement entails from the given trial information. The Adverse Events section lists the total number of adverse events and the number of cases of congestive heart failure for each cohort. Cohort 1 had a total of 1 adverse event, which was a case of congestive heart failure, out of 35 patients (2.86%), while cohort 2 had no adverse events, including congestive heart failure, out of 40 patients (0.00%). Therefore, the statement that the only case of congestive heart failure in the primary trial occurred in cohort 1 is true and consistent with the information provided in the trial's Adverse Events section."}
{"id": "8b91cab9-d858-45f3-bf8d-3d6fc55b4818", "result": "ENTAILMENT.\n\nThe statement accurately describes the information provided in the primary trial results section. The section reports two different measurements:\n\n1. Proportion of sentinel lymph nodes (SNs) detected by the Tc method (PTc) = 0.86\n2. Proportion of SNs detected by the ICG method (PICG) = 0.95\n\nTherefore, the statement entails from the given trial information."}
{"id": "4a75574c-fa86-4e62-a210-81c7b98a3807", "result": "CONTRADICTION.\n\nThe statement \"T4 N2 M4 patients are eligible for the primary trial\" contradicts the information provided in the Eligibility section of the primary trial. The trial excludes patients with T4 disease with ulceration of skin, infiltration of skin (except pathologically minimal dermal involvement), peau d'orange, or inflammatory breast cancer. Patients with T4 disease are only eligible if they have minimal dermal invasion. Therefore, T4 N2 M4 patients are not eligible for the primary trial."}
{"id": "d0b50aeb-aad8-4a8d-aae6-5c58a7d382c7", "result": "ENTAILMENT.\n\nThe statement accurately describes the information provided in the primary trial results section. The section reports two different measurements:\n\n1. Proportion of sentinel lymph nodes (SNs) detected by the Tc method (PTc) = 0.86\n2. Proportion of SNs detected by the ICG method (PICG) = 0.95\n\nThese measurements are reported for all three cohorts, as indicated by the \"Overall Number of Participants Analyzed\" field. Therefore, the statement entails from the given trial information."}
{"id": "b0b61978-57db-4a1c-812c-509e8b05f2dc", "result": "ENTAILMENT.\n\nThe statement accurately describes the information provided in the primary trial intervention section. Both cohorts receive identical interventions, with the only difference being the type of cancer that the patients have. Cohort 1 includes patients with triple-negative breast cancer (TNBC), while cohort 2 includes patients with non-small cell lung cancer (NSCLC). The intervention for both cohorts consists of Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24). Therefore, the statement entails from the given trial information."}
{"id": "24b85b44-b9e6-4c28-b3aa-1bd97102b7f1", "result": "CONTRADICTION.\n\nThe statement \"Patients must have a palpable carcinoma to be included in the primary trial\" contradicts the information provided in the Eligibility section of the primary trial. The Inclusion Criteria for Phase 1 and Phase 2 both state that patients with non-palpable tumors are eligible for the study, as long as they have a histologic diagnosis of invasive breast cancer or ductal carcinoma in situ, and the tumor is visible and enhances on prone MRI and is >1 cm in greatest diameter. Therefore, patients with non-palpable carcinomas can be included in the primary trial, which contradicts the statement."}
{"id": "fbb62216-2cf2-4813-ad41-12a86940610f", "result": "ENTAILMENT.\n\nThe statement \"Anaemia was the most common adverse event in cohort 1 and 2 of the primary trial\" entails from the given trial information. In cohort 1, anaemia was reported in 7/199 (3.52%) patients, which is the highest frequency among all adverse events listed. Similarly, in cohort 2, anaemia was reported in 2/36 (5.56%) patients, which is again the highest frequency among all adverse events listed. Therefore, the statement entails from the given information."}
{"id": "961a956e-fece-4baa-a2ad-d3a5320bd9d2", "result": "CONTRADICTION.\n\nThe statement \"The shortest PFS in cohort 1 of the primary trial was less than 3 weeks\" contradicts the information provided in the Results section of the primary trial. The median PFS for cohort 1 (NK105) was reported as 8.4 months (7.0 to 9.9), which is longer than 3 weeks. Therefore, the statement does not entail from the given trial information."}
{"id": "97fd111c-6969-43ab-93af-b3dff09960e5", "result": "CONTRADICTION.\n\nThe statement \"The adverse events section in the primary trial is reports the incidence rate of 12 different AEs\" contradicts the information provided in the Adverse Events section of the primary trial. The section reports that there were no adverse events (AEs) in the study, with a total of 0/0 AEs. Therefore, the statement does not entail from the given trial information."}
{"id": "eb1bfb08-eba0-4130-b328-00f56c0f84a6", "result": "CONTRADICTION.\n\nThe statement \"Diarrhoea is the most common adverse event in the primary trial and the secondary trial\" contradicts the information provided in the Adverse Events sections of both trials.\n\nIn the primary trial, diarrhoea is listed as an adverse event, but it is not the most common adverse event. The most common adverse events in the primary trial are neutropenia, thrombocytopenia, and cardiac arrest, which are reported in 4.62%, 3.08%, and 3.08% of patients, respectively.\n\nIn the secondary trial, diarrhoea is also listed as an adverse event, but it is not the most common adverse event. The most common adverse events in the secondary trial are anaemia, febrile neutropenia, and thrombocytopenia, which are reported in 1.27%, 0.85%, and 0.85% of patients, respectively.\n\nTherefore, the statement does not entail from the given trial information."}
{"id": "b1219e71-fbf5-4bba-8a93-a27ae444e3e1", "result": "ENTAILMENT.\n\nThe statement accurately summarizes the eligibility criteria for the primary trial. The inclusion criteria specify that patients must have confirmed hormone receptor positive advanced breast cancer and be postmenopausal women. The exclusion criteria state that patients who have received previous treatment for advanced breast cancer are not eligible, but previous treatment for early breast cancer is allowed. Therefore, the statement entails from the given trial information."}
{"id": "f10f3b84-e039-4a02-a98b-86d149d9a16f", "result": "ENTAILMENT.\n\nThe statement \"ongoing flucytosine treatments are not permitted for participants of the primary trial\" entails from the given trial information. The exclusion criteria for the trial specify that patients who are being treated with flucytosine are not eligible for the study. This means that patients who are currently receiving flucytosine treatment cannot participate in the primary trial."}
{"id": "0ddb07ae-6e70-436d-8723-f609e59c57da", "result": "ENTAILMENT.\n\nThe statement \"the primary trial participants receive doses of Pralatrexate that are calculated based on bodyweight\" entails from the given trial information. The Intervention section specifies that the study drug Pralatrexate is administered at a dose of 190 mg/m^2 for 2 to 4 weeks. This dose is calculated based on the patient's body surface area (BSA), which is typically calculated using the patient's weight and height. Therefore, the statement entails from the given trial information."}
{"id": "c10eea1a-5768-442d-ae07-20b4f8f4b583", "result": "CONTRADICTION.\n\nThe statement \"Only patients with triple negative breast cancer are eligible for the primary trial\" contradicts the given trial information. The trial includes patients with HER-2 positive breast cancer, as defined by an immunohistochemistry score of 3 or gene amplified by in-situ hybridization as defined by a ratio of greater than or equal to (>=) 2.0 for the number of HER2 gene copies to the number of chromosome 17 copies. Therefore, patients with triple negative breast cancer are not the only ones eligible for the primary trial."}
{"id": "2ef186d0-b4ab-44de-b785-a63e9e95851a", "result": "ENTAILMENT.\n\nThe statement \"most participants in the secondary trial and the primary trial did not suffer from Enterocolitis\" entails from the given trial information. In the primary trial, 11.98% of participants suffered from Adverse Events 1, which includes Enterocolitis. In the secondary trial, 24.45% of participants suffered from Adverse Events 1, which includes Enterocolitis, and 17.65% of participants suffered from Adverse Events 2, which also includes Enterocolitis. However, the majority of participants in both trials did not suffer from Enterocolitis, as the percentage of participants who experienced this adverse event is less than 50%. Therefore, the statement entails from the given trial information."}
{"id": "fef5aedb-21c0-4130-b8a3-cb1df5017c7a", "result": "ENTAILMENT.\n\nThe statement \"The adverse events section in the primary trial is empty\" entails from the given trial information. The Adverse Events section in the primary trial is shown to be empty, with a total of 0/0 adverse events reported. Therefore, the statement is true and entails from the given information."}
{"id": "2655c892-216e-4b96-a8f2-6f64403215c5", "result": "ENTAILMENT.\n\nThe statement \"there were 4 types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial\" entails from the given trial information. The four adverse events that did not affect any patients in cohort 1 are:\n\n1. Thrombocytopenia\n2. Anaemia\n3. Febrile neutropenia\n4. Leukopenia\n\nThe information provided in the Adverse Events section of the primary trial shows that none of the patients in cohort 1 experienced these adverse events. Therefore, the statement entails from the given information."}
{"id": "2825d63b-8f22-4fb8-829f-9567845251c6", "result": "CONTRADICTION.\n\nThe Eligibility section of the primary trial specifies that the study is open to adults aged 18 years or older, and that participants must be English speaking. Therefore, children cannot take part in the primary trial, as they do not meet the age requirement and may not be able to provide informed consent. The statement \"adults and children can take part in the primary trial\" contradicts the information provided in the Eligibility section."}
{"id": "6b35bc10-f591-4b84-abac-40a74be949fa", "result": "ENTAILMENT.\n\nThe Eligibility section of the primary trial specifies that participants must not have received prior treatment with fulvestrant or a phosphatidylinositol 3-kinase (PI3K) inhibitor. This means that individuals who have received either of these treatments are not eligible to participate in the trial. The statement \"Prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor is not admissible for the primary trial\" entails from the given trial information."}
{"id": "a5baab2c-9c32-4301-a574-4ba5a0c2eb00", "result": "ENTAILMENT.\n\nThe statement \"Presence of hot flashes for at least 4 months prior to study registration is required for all patients that want to participate in the primary trial or the secondary trial\" entails from the given trial information.\n\nIn the primary trial, patients must have bothersome hot flashes that have been present for 30 days prior to study registration. The duration of hot flashes is not specified in the secondary trial, but patients must have locally advanced breast cancer. Therefore, it is possible that patients in the secondary trial may have had hot flashes for less than 4 months prior to study registration.\n\nHowever, the statement does not contradict the trial information, as patients in the primary trial are required to have had hot flashes for at least 30 days prior to study registration, which is a subset of the 4 months required in the statement. Therefore, all patients in the primary trial would also meet the requirement of having hot flashes for at least 4 months prior to study registration."}
{"id": "70677d5f-7022-404c-8410-d1f89366d92f", "result": "ENTAILMENT.\n\nThe statement \"the secondary trial and the primary trial both measure the pCR and tumor diameter of their patient cohorts\" entails from the given trial information.\n\nThe primary trial measures the pCR rate as the number of patients with pathological complete response, which is defined as the absence of residual invasive cancer in both the breast and axillary lymph nodes. The secondary trial also measures the pCR rate, but it does not provide the exact definition of pCR used in the trial. However, it is reasonable to assume that the pCR rate measured in the secondary trial is similar to the pCR rate measured in the primary trial, as both trials are investigating the same disease (breast cancer) and the same treatment regimens.\n\nThe primary trial also measures tumor diameter, which is not explicitly mentioned in the secondary trial results. However, it is possible that tumor diameter was measured in the secondary trial, but the results were not reported in the given section.\n\nTherefore, the statement entails from the given trial information, as both trials measure pCR and tumor diameter, although the exact definition of pCR used in the secondary trial is not provided."}
{"id": "f46a7d27-a94f-4389-a1a0-4a8f5177b354", "result": "ENTAILMENT.\n\nThe statement \"None of the individual AEs recorded in the primary trial affect more than one patient\" entails from the given trial information.\n\nThe adverse events listed in the primary trial are:\n\n* Anaemia\n* Febrile neutropenia\n* Neutropenia\n* Pancytopenia\n* Thrombocytopenia\n* Acute coronary syndrome\n* Stress cardiomyopathy\n* Abdominal pain\n* Abdominal pain upper\n* Ascites\n\nEach of these adverse events is listed as affecting a specific number of patients, ranging from 0 to 4 patients. None of the adverse events affect more than 4 patients, which means that none of the individual AEs recorded in the primary trial affect more than one patient.\n\nTherefore, the statement entails from the given trial information."}
{"id": "fe876bb0-7ce3-4197-81ad-920f1f77938e", "result": "ENTAILMENT.\n\nThe statement \"there is a minimal difference between the results from the two primary trial cohorts\" entails from the given trial information.\n\nThe primary trial compares the event-free survival of patients receiving exemestane (25 mg) and anastrozole (1 mg) daily for 5 years. The results show that the percentage of participants with event-free survival at 5 years is 88% (87-89) for exemestane and 89% (88-90) for anastrozole.\n\nThe difference in event-free survival between the two cohorts is 1% (89% - 88%), which is a minimal difference. Therefore, the statement entails from the given trial information."}
{"id": "f45ff82d-e0f5-456a-9d78-ddc2dc6ab929", "result": "CONTRADICTION.\n\nThe given statement does not entail from the Primary Trial Eligibility criteria provided. The criteria specify that patients must be between 18 years and 70 years old, but there is no mention of a severe disability. Additionally, the criteria list adequate hepatic, renal, and heart functions, as well as adequate hematology levels, as requirements for eligibility, but they do not specify that these must be present in patients with a severe disability. Therefore, the statement does not logically follow from the given criteria."}
{"id": "4f705481-5dd0-414c-b375-c56e8c235b42", "result": "ENTAILMENT.\n\nThe statement \"The most common adverse event in the primary trial was skin infection\" entails from the given trial information. The adverse events listed in the primary trial include skin infection (2/41, 4.88%), which is the most common adverse event reported. Therefore, the statement is true and entails from the given information."}
{"id": "614d7ade-0fa7-4d77-bc19-1d3a2f2f48c2", "result": "CONTRADICTION.\n\nThe statement \"Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting most patients in the trial\" does not entail from the given trial information. According to the Adverse Events section, Febrile Neutropenia affected 3/56 patients (5.36%), which is not the most common adverse event recorded in the trial. The most common adverse event recorded in the trial was actually Constipation, which affected 1/56 patients (1.79%). Therefore, the statement is false and contradicts the given information."}
{"id": "c09fa61c-967a-40ae-96b0-c87b7cde237b", "result": "ENTAILMENT.\n\nThe statement \"None of the individual Aes recorded in the primary trial affect more than 10% of the population\" entails from the given trial information. The Adverse Events section lists the specific adverse events that occurred in the trial, along with their frequencies. None of the adverse events occurred in more than 10% of the population, as can be seen from the frequencies listed. For example, the most common adverse event, anemia, occurred in 4.00% of the population, while the least common adverse event, stress cardiomyopathy, occurred in 0.66% of the population. Therefore, the statement is true and entails from the given information."}
{"id": "4309860d-042d-45a4-8a0a-a9fdd075247a", "result": "CONTRADICTION.\n\nThe statement \"Cohort 1 and 2 of the primary trial do not receive NKTR-102 by infusion\" contradicts the information provided in the Intervention section of the primary trial. According to the Intervention section, NKTR-102 is administered to patients in Group A (Cohort 1) at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle. Therefore, patients in Cohort 1 do receive NKTR-102 by infusion.\n\nIt's worth noting that the statement is incorrect, and it's important to carefully review and ensure the accuracy of the information provided in the trial protocol, especially when it comes to the intervention and treatment regimens."}
{"id": "f2275929-7cfe-4bb1-a9f6-6bd0c4d5bf85", "result": "CONTRADICTION.\n\nThe primary trial and the secondary trial do not use identical outcome measurements. The primary trial measures Overall Response (CR, PR, or SD) of participants using Response Evaluation Criteria In Solid Tumors (RECIST), while the secondary trial measures Percentage of Participants With Pathological Complete Response (pCR) in Breast and Axilla as Defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer Staging System (in All Participants). The two outcome measurements are different, and therefore, the statement is false."}
{"id": "59cd7909-00c3-4c23-9a08-a42dbc8eabdd", "result": "ENTAILMENT.\n\nThe statement entails from the given trial information. The intervention description states that participants will be treated until disease progression, which means that the cycles will continue until the participant's disease progresses. The statement does not mention a set number of cycles that the participants will receive the intervention, which implies that the intervention will continue indefinitely until the disease progresses."}
{"id": "e6a4e9a6-56b8-4a30-9743-eb02688c090f", "result": "ENTAILMENT.\n\nThe statement entails from the given trial information. The trial inclusion criteria specify that subjects with operable, node-positive or high-risk node-negative HER2-positive breast carcinoma are eligible for the study. The trial definition of high-risk node-negative tumors includes tumors with a diameter of >2 cm or >1 cm with negative estrogen receptor/progesterone receptor (ER/PR) or malignancy grade 2-3 or presence of peritumoral vascular invasion or age <35 years.\n\nA patient with a node-positive T2 N2 M0 adenocarcinoma of the breast would meet the trial criteria for high-risk node-positive tumors and would therefore be eligible for the study.\n\nSimilarly, a patient with a node-negative adenocarcinoma of the breast with a tumor diameter of 1.5 cm would also meet the trial criteria for high-risk node-negative tumors and would be eligible for the study.\n\nIt's worth noting that there are other eligibility criteria mentioned in the trial protocol, such as adequate bone marrow, renal and liver function, absence of metastatic disease, and absence of certain cardiovascular conditions, but these criteria do not appear to be relevant to the patients described in the statement."}
{"id": "82a3e542-f784-44d7-90f6-34d7e969283c", "result": "ENTAILMENT.\n\nThe statement entails from the given trial information. The intervention description states that all patients received Avastin (Bevacizumab) 15 mg/kg IV every three weeks as well as continuing with hormonal therapy they previously were taking. This means that the patients received at least two types of medications during the study: Avastin and hormonal therapy. Therefore, the statement is entailed by the trial information."}
{"id": "fb360514-14be-45ab-8b74-ea5a7eb181d7", "result": "CONTRADICTION.\n\nThe statement does not entail from the given trial information. The primary trial reports adverse events, specifically stating that there were no adverse events (0/23, 0.00%) in the Adverse Events 1 section. Similarly, the secondary trial also reports adverse events, with zero adverse events (0/655, 0.00%) in Adverse Events 1 and zero adverse events (0/580, 0.00%) in Adverse Events 2. Therefore, the statement that the primary trial and the secondary trial do not report adverse events is incorrect."}
{"id": "7137dec6-5c98-4156-8035-7bbaaf0b649d", "result": "ENTAILMENT.\n\nThe statement entails from the given trial information. The PRIMARY TRIAL ELIGIBILITY section states that one of the inclusion criteria is an Eastern Cooperative Oncology Group (ECOG) score of 0 or 1. This means that patients with an ECOG score of 2 or higher are not eligible for the primary trial. Therefore, the statement that ECOG score < 2 is necessary to be eligible for the primary trial is entailed by the trial information."}
{"id": "015dd869-db90-45a9-a951-9dc7dc2b2e01", "result": "CONTRADICTION.\n\nThe statement contradicts the given trial information. The PRIMARY TRIAL ELIGIBILITY section states that patients with cancer that has spread to the brain are excluded from the trial. Therefore, patients with a malignant brain tumour are not eligible for the primary trial.\n\nAdditionally, the trial information does not mention colon cancer diagnosis as an exclusion criterion. However, it does state that patients with another cancer diagnosis within the last 5 years are excluded from the trial. Therefore, patients with a colon cancer diagnosis may be eligible for the primary trial if they meet the other eligibility criteria and have not had treatment for another cancer within the last 5 years."}
{"id": "3a4003f6-ff1c-43d8-be48-f767266b2cf5", "result": "ENTAILMENT.\n\nThe statement entails that the secondary trial and the primary trial have different inclusion and exclusion conditions. The secondary trial includes patients with ErbB2(HER2)overexpressing breast cancer, brain lesion(s) that are progressing, and prior treatment of brain metastases with Whole Brain Radiotherapy (WBR) and/or Stereotactic Radiosurgery (SRS), while the primary trial includes patients with invasive adenocarcinoma of the breast confirmed at MSKCC, evidence of recurrent or progressive locally advanced or metastatic breast cancer, and presence of at least one measurable metastatic lesion.\n\nThe secondary trial excludes patients with a history of immediate or delayed hypersensitivity reaction to gadolinium contrast agents, pre-existing severe cerebral vascular disease, such as stroke involving a major vessel, and serious medical or psychiatric disorder that would interfere with the patient's safety or informed consent. The primary trial excludes patients with a prior severe allergic reaction to paclitaxel therapy, presence of new or recurrent pleural effusion which is symptomatic and/or requiring medical intervention, and concurrent medical condition which may increase the risk of toxicity.\n\nTherefore, the inclusion and exclusion conditions of the secondary trial are different from those of the primary trial, which entails the statement."}
{"id": "47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7", "result": "ENTAILMENT.\n\nThe statement suggests that at least two participants, one from each cohort, had a Progression-Free Survival (PFS) of 10.8 months. The trial results provide the median PFS for each arm, which is 9.1 months (6.8-10.8) for the Paclitaxel/Bevacizumab/Everolimus arm and 7.1 months (5.6-10.8) for the Paclitaxel/Bevacizumab/Placebo arm.\n\nSince the median PFS for both arms is lower than 10.8 months, it means that at least some participants in each arm had a PFS of greater than 10.8 months. Therefore, the statement entails from the given trial information."}
{"id": "f3cb9150-32c6-4877-9a87-4fac45a24948", "result": "ENTAILMENT.\n\nThe information provided in the primary trial states that there were no adverse events of any kind recorded in the trial. In contrast, the secondary trial reports several adverse events, including one case of Musculoskeletal adverse event in cohort 2. Therefore, it is true that all the recorded cases of Musculoskeletal adverse events occurred in cohort 2 of the secondary trial, as there were no such cases in the primary trial."}
{"id": "9d8b26d6-d574-4717-88b6-77458bc683f3", "result": "CONTRADICTION.\n\nThe information provided in the primary trial's Adverse Events section does not support the statement that syncope was the most common adverse event recorded in the trial. According to the information provided, the most common adverse events were infection, pain, muscle weakness, and dyspnea, with a frequency of 3.64%, 1.82%, 1.82%, and 1.82%, respectively. Syncope is not listed as an adverse event in the primary trial. Therefore, the statement that syncope was the most common adverse event recorded in the primary trial is false."}
{"id": "51be7c95-8da4-419c-950c-91ebdd2c3fe5", "result": "CONTRADICTION.\n\nThe statement suggests that all patients in the primary trial receive higher doses of BKM120 than patients in the secondary trial. However, the information provided in the primary trial's Intervention section indicates that patients received either BKM120 and Paclitaxel or Placebo and Paclitaxel, while the secondary trial's Intervention section mentions that patients breathe through the Active Breathing Coordinator (ABC) device. There is no mention of BKM120 in the secondary trial's Intervention section. Therefore, the statement that all patients in the primary trial receive higher doses of BKM120 than patients in the secondary trial is false."}
{"id": "07042b0f-d422-49c3-8d53-81319927a4b3", "result": "Sure, here's a numbered list of the inclusion and exclusion criteria for the secondary trial:\n\n\nInclusion Criteria:\n\n1. Patients with metastatic or advanced solid tumors\n2. Women with histologically or cytologically confirmed triple negative breast cancer\n3. Participants with histologically or cytologically confirmed pancreatic adenocarcinoma\n4. Patients with histologically or cytologically confirmed Non Small Cell Lung Cancer (NSCLC)\n\n5. Patients may have received prior chemotherapy\n6. Patients may have received prior radiation therapy\n7. Patients may have stable brain metastases\n8. Patients with controlled Type 1 or 2 diabetes mellitus\n9. Patients with stable chronic hepatitis B or C virus infection\n10. Patients with stable renal function, as defined by the protocol\n11. Patients with stable bone marrow function, as defined by the protocol\n12. Patients who have completed preoperative chemotherapy, as defined by the protocol\n13. Patients who have been on a stable dose of aspirin (<325 mg/day) or standard non-steroidal anti-inflammatory agents for more than two weeks with stable INR\n\n\nExclusion Criteria:\n\n1. Active brain metastases or leptomeningeal metastases\n2. Any serious or uncontrolled medical disorder that, in the opinion of the investigator, would compromise the patient's ability to participate in the trial or interpret the results\n3. Prior malignancy within the previous 3 years, except for non-melanomatous skin cancer\n4. Patients with significant residual invasive disease after preoperative chemotherapy, as assessed by clinical examination and/or imaging studies\n5. History of bleeding diathesis or coagulopathy\n6. History of grade 3 or 4 allergic reactions to compounds of similar chemical or biological composition to cyclophosphamide (such as other alkylating agents) or methotrexate (such as other antimetabolites)\n7. Patients with large or rapidly accumulating pleural or abdominal effusions\n8. Patients with uncontrolled intercurrent illness\n9. Patients receiving other investigational agents while on study\n10. Patients who have received chemotherapy within 28 days prior to enrollment\n11. Patients who have not recovered from previous surgery or radiation therapy\n12. Patients with significant residual disease on pathologic review following preoperative chemotherapy\n13. Patients with known HIV infection\n14. Patients who are pregnant, expect to become pregnant, plan to conceive a child while on study, or are breastfeeding\n15. Patients with any history of arterial thromboembolic events, including transient ischemic attack (TIA), cerebrovascular accident (CVA), unstable angina, or myocardial infarction (MI) within the past 6 months\n16. Patients with any history of malignancy treated without curative intent, excluding non-melanomatous skin cancer\n17. Patients with clinically significant peripheral artery disease, as measured by clinical examination or imaging studies\n18. Patients with significant residual invasive disease on pathologic review following preoperative chemotherapy\n19. Patients who have received radiation therapy within 28 days prior to enrollment\n20. Patients with a history of grade 3 or 4 allergic reactions to compounds of similar chemical or biological composition to cyclophosphamide (such as other alkylating agents) or methotrexate (such as other antimetabolites)\n\nNote that some exclusion criteria may vary depending on the specific trial and protocol version. It's important to consult the protocol and trial-specific documentation for the most up-to-date and accurate information."}
{"id": "32361e21-ee57-4c34-9390-833ba5048a10", "result": "Contradiction.\n\nThe primary trial intervention describes Fulvestrant being administered intramuscularly (in the gluteus maximus) and Everolimus being administered orally. The statement suggests that Fulvestrant is administered intramuscularly (to the deltoid), which contradicts the information provided in the primary trial intervention."}
{"id": "88668508-dfd4-4a39-91cd-cf1654a6dfc4", "result": "Contradiction.\n\nThe primary trial reports the local control using ipsilateral breast tumor recurrence rates as the outcome measurement, and the results are presented in terms of the percentage of participants who experience dermatitis. The statement suggests that the primary trial does not report the PFS or objective response rate of its patient cohort, which contradicts the information provided in the trial results."}
{"id": "dca4c9f7-bb2a-4f73-b390-93b7ced87c73", "result": "Entailment.\n\nThe statement suggests that the results from the secondary trial and the primary trial are non-comparable, which entails from the given trial information. The primary trial reports the outcome measurement of complete pathologic response, while the secondary trial reports the change in Masood score. The two outcomes are different and cannot be compared directly. Additionally, the scales used in the two trials are different, with the primary trial using a semi-quantitative score ranging from 0 to 24, while the secondary trial uses a scale ranging from -1.1 to 1.9. Therefore, the results from the two trials cannot be compared directly."}
{"id": "e7604382-09cd-43b4-998f-a51b33f25c5a", "result": "Contradiction.\n\nThe primary trial intervention involves intraductal administration of dextrose or dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD) prior to conventional surgery for breast cancer. This implies that the participants in the primary trial do receive medication, specifically dextrose or dextrose with PLD, albeit not orally.\n\nOn the other hand, the secondary trial intervention involves cetuximab given IV over 60-120 minutes once a week, and patients not responding to treatment may cross over to arm II, which includes cetuximab and carboplatin. This means that the participants in the secondary trial do receive medication orally, specifically cetuximab, which contradicts the statement.\n\nTherefore, the statement \"the primary trial and the secondary trial participants do not receive any medication orally\" does not entail from the given trial information."}
{"id": "75affd49-4905-4d43-9a5c-ef795281bac4", "result": "Contradiction.\n\nThe results of the primary trial show that the Overall Response Rate (ORR) for Arm A (Liposomal Doxorubicin) was 28% (16 to 42), while the ORR for Arm B (Docetaxel) was 31% (18 to 45). Since both arms had an ORR of more than 40%, the statement \"neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients\" does not entail from the given trial information."}
{"id": "2e76c74a-b6dd-47d8-a674-c1e80b0a3a65", "result": "Contradiction.\n\nThe PRIMARY TRIAL ELIGIBILITY section states that patients must have confirmed hormone receptor positive advanced breast cancer and be postmenopausal women. However, it also states that patients who have received previous treatment for advanced breast cancer are excluded from the trial. This means that patients who have received prior chemotherapy for their advanced breast cancer would not be eligible for the trial, which contradicts the statement."}
{"id": "8c6314f7-34f5-42a7-ba66-b95d050a6315", "result": "Contradiction.\n\nThe statement \"The shortest PFS in cohort 1 of the primary trial was 1.4 months below average\" implies that the shortest PFS in cohort 1 was 1.4 months less than the average PFS in cohort 1. However, the results provided in the PRIMARY TRIAL RESULTS section show that the median PFS for cohort 1 (NK105) was 8.4 months, and the median PFS for cohort 2 (Paclitaxel) was 8.5 months. Since the median PFS for both cohorts is above 8 months, it is not possible for the shortest PFS in cohort 1 to be 1.4 months below average. Therefore, the statement does not entail from the given trial information."}
{"id": "f114846e-79d8-4712-add0-bb34b65d418f", "result": "Contradiction.\n\nThe statement \"there were 6 recorded deaths in cohort 1 of the primary trial and 7 in cohort 2\" implies that there were a total of 13 deaths in both cohorts. However, the results provided in the PRIMARY TRIAL RESULTS section show that the number of patients event-free at 12 months was 6 in cohort 1 (Fulvestrant + Anastrozole) and 7 in cohort 2 (Anastrozole). This means that there were no deaths in cohort 1 and 1 death in cohort 2, which contradicts the statement."}
{"id": "812bd63c-4bfb-49cb-8fa9-baa3f8f6dabe", "result": "Contradiction.\n\nThe PRIMARY TRIAL RESULTS section reports the change in tumor size (CTS) from baseline to the end of Cycle 2, not the changes in the number of lesions. The CTS is calculated as the log ratio of tumor size at Cycle 2 to tumor size at baseline, where the tumor size is the sum of the target lesion measurements at each assessment. Therefore, the statement does not entail from the given trial information."}
{"id": "b1d28450-fc7d-496a-9c7c-bf711b28f8e4", "result": "Contradiction.\n\nThe PRIMARY TRIAL ELIGIBILITY section states that patients who are pregnant are excluded from the trial. Therefore, it is not possible for any pregnant patients to be accepted into the trial, let alone have undergone prior treatment for breast cancer with endocrine therapy. The statement entails a logical contradiction and is therefore false."}
{"id": "c7dc582a-4a58-4cb5-b980-b2d2b6a128c3", "result": "Contradiction.\n\nThe Adverse Events section of the primary trial mentions that 1/30 patients (3.33%) experienced diarrhea, which is a gastrointestinal adverse event. Therefore, the statement that no gastrointestinal adverse events were recorded in the primary trial is false.\n\nAdditionally, the statement that no cardiac or neural adverse events were recorded in the primary trial is also false, as the Adverse Events section mentions that 1/30 patients (3.33%) experienced dry eyes, which is an ocular adverse event that could potentially be related to cardiac or neural effects.\n\nTherefore, the statement that no cardiac or neural adverse events were recorded in the primary trial is a contradiction to the information provided in the Adverse Events section of the trial."}
{"id": "a805f174-2707-4302-a195-05153ea8523e", "result": "Entailment.\n\nThe PRIMARY TRIAL ELIGIBILITY section states that participants must be 18 years old or older, which means that only adults can take part in the primary trial. This entails that the statement \"Only adults can take part in the primary trial\" is true."}
{"id": "e4aeb013-7713-4b73-acbd-f8379cc6a494", "result": "Entailment.\n\nThe Adverse Events section of the primary trial shows that in Cohort 1, there were 0/101 (0.00%) patients with slipped disks, while in Cohort 2, there were 1/98 (1.02%) patients with slipped disks. This means that the percentage of patients with slipped disks in Cohort 2 (1.02%) is higher than the percentage of patients with slipped disks in Cohort 1 (0.00%).\n\nTherefore, the statement \"there was a higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1\" entails from the given trial information."}
{"id": "b8eaa8fd-61cf-4ca9-aaec-267d61c1fae3", "result": "Contradiction.\n\nThe statement suggests that all patients in cohort 1 of the primary trial had a PFS of over 7 months, with the highest PFS being just under 10 months. However, the results provided in the PRIMARY TRIAL RESULTS section indicate that the mean PFS for arm 1 (neratinib plus capecitabine) was 8.8 months, with a 95% confidence interval of 7.8 to 9.8 months. This means that some patients in cohort 1 may have had a PFS of less than 7 months, and the highest PFS was not necessarily just under 10 months. Therefore, the statement does not entail from the given trial information."}
{"id": "2729a321-709b-4392-9604-dd7237bedb17", "result": "Entailment.\n\nThe statement suggests that the majority of participants in cohort 1 and 2 of the primary trial achieved Disease-free Survival for 5 years. The results provided in the PRIMARY TRIAL RESULTS section show that the percentage of patients alive and cancer-free at 5 years was 80.1% (78.0 to 82.0) for arm 1 (TAC x 6) and 82.2% (80.2 to 84.0) for arm 2 (AC x 4 then P x 4). Since both arms had a majority of patients achieving Disease-free Survival for 5 years, the statement entails from the given trial information."}
{"id": "8e9611fc-89f8-44cb-af09-8d71a13ca082", "result": "Entailment.\n\nThe statement suggests that cohort 1 and 2 of the primary trial do not receive the same intervention. The intervention for cohort 1 is NKTR-102, while the intervention for cohort 2 is Treatment of Physician's Choice (TPC), which allows the physician to choose from a list of 7 chemotherapy agents. Since the interventions are different, the statement entails from the given trial information."}
{"id": "b9491012-49ba-4eb1-8230-1966f54ea012", "result": "Entailment.\n\nThe statement suggests that patients with extracranial metastases can be eligible for the primary trial. The eligibility criteria for the trial specify that patients must have histologically or cytologically confirmed breast cancer with radiographically confirmed metastases to the brain, and that extracranial metastases are allowed. Therefore, patients with extracranial metastases can meet the eligibility criteria and be enrolled in the trial."}
{"id": "62e449ad-16b3-479d-94a5-ffc435b5e99c", "result": "Entailment.\n\nThe statement \"patients with a Malignant brain tumour diagnosis are excluded from the primary trial\" entails from the given trial information. The exclusion criteria for the trial specify that patients with cancer that has spread to the brain are not eligible for the trial. This means that patients with a malignant brain tumour diagnosis, which is a type of cancer that has spread to the brain, are excluded from the trial."}
{"id": "565d7982-aa9a-4c01-987c-1d67bc9c212d", "result": "Contradiction.\n\nThe statement \"ongoing flucytosine treatments are necessary for all participants of the primary trial, treatments must have started at least 6 months before study entry\" contradicts the exclusion criteria for the trial, which states that patients being treated with flucytosine are not eligible for the study. The exclusion criteria also specify that patients who are being treated with other pyrimidine fluoride antineoplastic agents (including any combination therapy) are not eligible for the study. Therefore, the statement that all participants must have ongoing flucytosine treatments is not consistent with the trial's eligibility criteria."}
{"id": "7271e0db-bb82-423f-ad95-5ffa84fab97e", "result": "Entailment.\n\nThe statement \"There are more cases of Urosepsis in the primary trial than in the secondary trial\" entails from the given trial information. The primary trial reports 2 cases of Urosepsis out of 12 patients (16.67%), while the secondary trial reports 0 cases of Urosepsis out of 65 patients (0.00%). Therefore, the statement is true."}
{"id": "6402e13a-7cfb-4774-b7f9-80ecb79fda2a", "result": "Contradiction.\n\nThe statement \"the primary trial participants are not administered any oral medication whereas the secondary trial patients only receive treatment orally\" contradicts the information provided in the Intervention sections of the primary and secondary trials.\n\nThe primary trial Intervention section describes Positron Emission Mammography (PEM) scans, mammography, DCE-MRI, US of the breast and axilla, and ultrasound guided biopsy of axillary lymph node, which are all imaging and diagnostic procedures, but does not mention any oral medication.\n\nThe secondary trial Intervention section, on the other hand, describes exemestane and anastrozole, which are both oral medications, and states that they will be administered to patients orally.\n\nTherefore, the statement is incorrect, as the primary trial does not involve any oral medication, while the secondary trial does involve oral medication."}
{"id": "734423d5-4b47-4448-ab98-811015d626f0", "result": "Entailment.\n\nThe statement \"There were multiple patients which suffered Neutropenia in both cohorts of the primary trial\" entails from the given trial information. The PRIMARY TRIAL ADVERSE EVENTS section reports that Neutropenia occurred in 1/39 patients (2.56%) in Adverse Events 1 and in 1/21 patients (4.76%) in Adverse Events 2. Therefore, Neutropenia was experienced by multiple patients in both cohorts of the primary trial."}
{"id": "e9fd065c-342c-4dfb-9c1c-a4c0c44d0acd", "result": "Contradiction.\n\nThe statement \"All the primary trial participants are administered Anastrazole in a pill form, but none of the secondary trial receive any Anastrazole\" contradicts the information provided in the PRIMARY TRIAL INTERVENTION and SECONDARY TRIAL INTERVENTION sections.\n\nIn the PRIMARY TRIAL INTERVENTION section, it is mentioned that Arm A participants receive 1 mg Anastrazole per day in pill form, while Arm B participants receive 1 placebo pill per day. This implies that all primary trial participants receive Anastrazole in a pill form.\n\nOn the other hand, in the SECONDARY TRIAL INTERVENTION section, it is mentioned that Phase 1 - Cohort A participants receive dual treatment with 1 mg Anastrazole orally once daily together with AZD0530 175 mg orally once daily, or as specified per protocol, until disease progression for treatment of metastatic breast cancer. This implies that some secondary trial participants receive Anastrazole, contradicting the statement.\n\nTherefore, the statement \"All the primary trial participants are administered Anastrazole in a pill form, but none of the secondary trial receive any Anastrazole\" does not entail from the given trial information."}
{"id": "32ed503c-1cfd-44f6-b8bb-23d9d175d73d", "result": "Entailment.\n\nThe PRIMARY TRIAL ELIGIBILITY section states that patients must be able to lie still for 1.5 hours for PET scanning, and that PET scanning is required for study participation. Therefore, patients who are unable to undergo a PET scan are excluded from participating in the primary trial. This entails that patients must be able to undergo a PET scan to participate in the primary trial."}
{"id": "175044aa-72b1-405d-8506-30002f5098e4", "result": "Contradiction.\n\nThe PRIMARY TRIAL ADVERSE EVENTS section states that there were no adverse events in the study. This means that there were no instances of hypotension, hemorrhage, or bradycardia reported in the study. Therefore, the statement that the adverse events section describes the number of patients who suffered these events is contradictory to the information provided in the PRIMARY TRIAL ADVERSE EVENTS section."}
{"id": "045ad91e-44fa-42cc-ac22-a7aab26a9009", "result": "Contradiction.\n\nThe PRIMARY TRIAL INTERVENTION section states that the intervention consists of Avastin (Bevacizumab) 15 mg/kg IV every three weeks in addition to continuing with hormonal therapy. It does not mention radiotherapy as part of the intervention. Therefore, the statement that the primary trial participants are administered Avastin, Bevacizumab, and radiotherapy as part of the intervention is a contradiction to the information provided in the PRIMARY TRIAL INTERVENTION section."}
{"id": "00822101-fa21-4a26-bf45-3b1f535da005", "result": "Contradiction.\n\nThe PRIMARY TRIAL ELIGIBILITY section states that patients with HER2-positive status are eligible for the study, as long as they have unknown HER2 status or for whom determination of HER2 status is not possible. This contradicts the statement that a patient with a HER2-positive status cannot take part in the primary trial."}
{"id": "06f798d1-2956-4903-83e9-58a41fa425f7", "result": "Entailment.\n\nThe PRIMARY TRIAL ADVERSE EVENTS section states that there were no adverse events recorded in the trial, and the SECONDARY TRIAL ADVERSE EVENTS section also states that there were no adverse events recorded in the trial. Therefore, it entails that the primary trial and the secondary trial do not record any cardiac or infection related adverse events."}
{"id": "8648c7df-582a-42a9-9330-414b2430ac56", "result": "Contradiction.\n\nThe statement suggests that none of the individual adverse events in the primary trial affect more than 100 patients, and that in total, less than 30 patients suffer adverse events. However, the PRIMARY TRIAL ADVERSE EVENTS section shows that there are several adverse events that affect more than 100 patients, such as anemia (10/1612, 0.62%), blood and lymphatic system disorders - other (3/1612, 0.19%), febrile neutropenia (7/1612, 0.43%), cardiac disorders - other (6/1612, 0.37%), conduction disorder (2/1612, 0.12%), myocardial infarction (6/1612, 0.37%), and palpitations (1/1612, 0.06%). Additionally, the total number of patients who experienced adverse events is 340/1612 (21.09%) for Adverse Events 1 and 350/1623 (21.57%) for Adverse Events 2, which is higher than the stated limit of 30 patients. Therefore, the statement is in contradiction with the information provided in the PRIMARY TRIAL ADVERSE EVENTS section."}
{"id": "89f610a7-9e81-43a4-8c1e-5503233b2be1", "result": "Entailment.\n\nThe PRIMARY TRIAL ELIGIBILITY section states that patients must have a pathologically confirmed diagnosis of breast cancer with documented progressive disease to be eligible for the trial. Therefore, the statement that breast cancer patients must have documented stable disease to participate in the primary trial entails from the given trial information."}
{"id": "b0046821-ba27-4a90-8869-cb708b843aa4", "result": "Contradiction.\n\nThe PRIMARY TRIAL INTERVENTION section states that all participants in the primary trial receive flaxseed, either in combination with anastrozole (Arm A) or as a single agent (Arm B). However, the SECONDARY TRIAL INTERVENTION section states that none of the participants in the secondary trial receive flaxseed. This contradicts the statement that all primary trial participants are administered flaxseed."}
{"id": "d1b217ae-76f3-4ba6-958e-5b2558703ba4", "result": "Entailment.\n\nThe PRIMARY TRIAL ADVERSE EVENTS section states that there was a total of 1 adverse event (congestive heart failure) in cohort 1, which accounts for 2.86% of the total number of patients in that cohort. Meanwhile, there were no adverse events reported in cohort 2. Therefore, the statement that several cases of congestive heart failure occurred in cohort 1 but none in cohort 2 entails from the given trial information."}
{"id": "8ddf8b88-6e06-4c71-9e28-45f73a637af0", "result": "Contradiction.\n\nThe PRIMARY TRIAL INTERVENTION section states that patients receive bilateral breast and axillary PEM scans, bilateral mammography, DCE-MRI, US of the breast and axilla, and ultrasound guided biopsy of axillary lymph node if suspicious, which are all imaging techniques and not oral or topical medications. The SECONDARY TRIAL INTERVENTION section states that patients receive oral exemestane or anastrozole, which are oral medications. Therefore, the statement that primary trial participants are administered oral and topical medication, whereas secondary trial patients only receive treatment orally, is not accurate and contradicts the information provided in the trial protocol."}
{"id": "0ea29bd5-20be-40ea-8ad7-705d283d1d48", "result": "Contradiction.\n\nThe PRIMARY TRIAL RESULTS section states that the outcome measurement for disease-free survival was the percentage of patients alive and cancer-free at 5 years, and the results for Groups 1 and 2 were 80.1% (78.0-82.0) and 82.2% (80.2-84.0), respectively. These results indicate that the majority of participants in cohorts 1 and 2 did not suffer from disease recurrence, contralateral breast cancer, second primary cancer, or death from any cause prior to recurrence or second primary cancer, since the percentage of patients alive and cancer-free is greater than 80%. Therefore, the statement that the majority of participants in cohorts 1 and 2 suffered some kind of disease recurrence or death contradicts the information provided in the trial results."}
{"id": "e147796d-2edd-42d1-ac53-300fb8bd5eb6", "result": "Contradiction.\n\nThe PRIMARY TRIAL INTERVENTION section describes two interventions: lapatinib 1500 mg and placebo. However, the statement suggests that 80% of patients received a placebo intervention, which is not consistent with the information provided in the PRIMARY TRIAL INTERVENTION section.\n\nAccording to the PRIMARY TRIAL INTERVENTION section, participants were randomly assigned to receive either lapatinib 1500 mg or placebo orally once daily. Therefore, the percentage of patients who received a placebo intervention should be approximately 50%, not 80%.\n\nTherefore, the statement \"80% of patients in the primary trial received a placebo intervention\" contradicts the information provided in the PRIMARY TRIAL INTERVENTION section of the clinical trial."}
{"id": "6b33b4ae-36f2-4a53-a954-6f246f6e023d", "result": "Entailment.\n\nThe PRIMARY TRIAL ELIGIBILITY section states that participants must have a known and documented HER2-positive status and a left ventricular ejection fraction (LVEF) of at least 50% to be eligible for the trial. This means that patients wanting to take part in the primary trial must have these characteristics, which are included in the inclusion criteria.\n\nTherefore, the statement \"Patients wanting to take part in the primary trial must have a Known and documented HER2+ status and an LVEF of at least 50 percent (%)\" entails from the given trial information."}
{"id": "06fad978-1dc3-46f5-b45f-5ac6577f28b9", "result": "Contradiction.\n\nThe PRIMARY TRIAL ELIGIBILITY section states that participants must have a histologic or cytologic diagnosis of advanced breast cancer, and notes that lesions should not be amenable to surgery or radiation of curative intent. Additionally, the trial requires participants to have a performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG) performance status scale, and to have received prior chemotherapy containing anthracyclines and taxanes.\n\nThe SECONDARY TRIAL ELIGIBILITY section, on the other hand, states that participants must have confirmed hormone receptor positive advanced breast cancer, and notes that postmenopausal women are eligible. However, the secondary trial excludes patients who have previously received treatment for advanced breast cancer.\n\nThe statement \"Patients must be female and have confirmed advanced colon cancer to be eligible for the secondary trial and the primary trial\" is inaccurate, as the PRIMARY TRIAL ELIGIBILITY section does not mention anything about colon cancer, and the SECONDARY TRIAL ELIGIBILITY section specifically states that participants must have confirmed hormone receptor positive advanced breast cancer. Therefore, this statement contradicts the information provided in the trial protocol."}
{"id": "878c09e7-3fd9-404e-921e-5b549e9578fb", "result": "Entailment.\n\nThe table provided in the PRIMARY TRIAL RESULTS section shows the number of participants who experienced adverse events (AEs) of different grades. The data shows that the majority of participants (53, or 75.7%) experienced Grade 1 AEs, followed by Grade 2 AEs (40, or 57.1%), Grade 3 AEs (18, or 25.7%), Grade 4 AEs (2, or 2.9%), and Grade 5 AEs (12, or 17.1%).\n\nTherefore, the statement \"Most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade 4\" entails from the given trial information."}
{"id": "3a0c517d-9b9a-4497-9675-50ff12cd02b7", "result": "Contradiction.\n\nAccording to the Adverse Events 1 table, there were 2 cases of Left ventricular dysfunction and 1 case of Abdominal pain in cohort 1 of the primary trial. Therefore, the statement \"in cohort 1 of the primary trial there were more cases of Left ventricular dysfunction than Abdominal pain\" does not entail from the given trial information."}
{"id": "9abb10d7-496e-44fd-915d-d86aedf6c9b6", "result": "Contradiction.\n\nThe PRIMARY TRIAL ELIGIBILITY section states that participants must have a known and documented HER2-positive status, but it does not mention anything about TNBC (triple-negative breast cancer) status. Additionally, the section mentions that participants must have a known and documented LVEF of at least 50%, but it does not specify that this must be documented for patients with TNBC. Therefore, the statement \"Patients wanting to take part in the primary trial must have a Known and documented TNBC status and an LVEF of at least 50 percent (%)\" does not entail from the given trial information."}
{"id": "8460a212-8054-4bd2-b4e6-af1d137a2f79", "result": "Entailment.\n\nThe PRIMARY TRIAL RESULTS section reports the objective response rate (ORR) using the percentage of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria on treatment. The SECONDARY TRIAL RESULTS section reports the proportion of sentinel lymph nodes (SLNs) flagged by the two methods using the number of Tc-positive and ICG-positive sentinel nodes (SNs) detected, the number of Tc-positive and ICG-negative SNs detected, and the number of Tc-negative and ICG-positive SNs detected. The total number (N) of SNs detected is also reported.\n\nTherefore, the statement \"the primary trial and the secondary trial report their results using different units of measure\" entails from the given trial information. The PRIMARY TRIAL RESULTS section uses percentage of participants achieving CR or PR as the unit of measure, while the SECONDARY TRIAL RESULTS section uses the number of SNs detected and the proportion of SNs detected by each method as the unit of measure."}
{"id": "a3390ae6-d41d-4dc7-899e-de9534adfd6b", "result": "Contradiction.\n\nThe PRIMARY TRIAL INTERVENTION section states that participants received lapatinib 1250 mg and capecitabine 2000 mg/m^2. This means that the dose of capecitabine was 2000 mg/m^2, which is significantly higher than the dose of lapatinib, which was 1250 mg.\n\nTherefore, the statement \"the primary trial participants receive significantly higher doses of Capecitabine than of Lapatinib\" contradicts the given trial information."}
{"id": "17bbea92-8f92-41f3-9b9d-cf6e62cf6798", "result": "Entailment.\n\nThe PRIMARY TRIAL RESULTS section reports the incidence of dose-limiting toxicity (DLT) in subjects with solid tumors treated with neratinib in combination with paclitaxel. The results show that 0% of participants in both the neratinib 160 mg + paclitaxel 80 mg/m\u00b2 and neratinib 240 mg + paclitaxel 80 mg/m\u00b2 arms experienced DLT.\n\nThe statement \"the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer side effects that are serious enough to prevent an increase in dose or level of that treatment\" entails from the given trial information, as the results provide information on the incidence of DLT in patients treated with neratinib and paclitaxel."}
{"id": "794269ca-e7ec-4a65-ace5-b0f24a8cdc15", "result": "Entailment.\n\nThe PRIMARY TRIAL RESULTS section reports the percentage of participants with objective response (OR) in the ixabepilone 40 mg/m^2 and cetuximab 250 mg/m^2 + ixabepilone 40 mg/m^2 arms, using Response Evaluation Criteria in Solid Tumors (RECIST) to assess tumor response. The SECONDARY TRIAL RESULTS section reports the progression-free survival (PFS) in the NK105 and paclitaxel arms, using RECIST to assess disease progression.\n\nThe statement \"the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures PFS\" entails from the given trial information, as the primary trial focuses on assessing the response rate of participants in different treatment arms, while the secondary trial focuses on assessing the duration of progression-free survival in those treatment arms."}
{"id": "4dfff980-6a2b-4f01-9194-6ec831d6fed7", "result": "Entailment.\n\nThe Adverse Events section of the primary trial reports that Infection was the most common adverse event, occurring in 2/55 (3.64%) of participants. This entails that Infections were the most common adverse events recorded in the primary trial."}
{"id": "dc4c57b0-8c75-494e-81b0-3528df85ebff", "result": "Contradiction.\n\nThe SECONDARY TRIAL RESULTS section reports the Overall Survival (OS) of patients in the NKTR-102 and Treatment of Physician's Choice (TPC) arms, with a median OS of 7.8 months (95% CI: 6.1-10.2) and 7.5 months (95% CI: 5.8-10.4), respectively. This contradicts the statement that neither the secondary trial nor the primary trial record the Overall Survival (OS) of Patients in their cohorts."}
{"id": "8d9f94e3-871b-4fb4-a522-0a73d9d0ec3c", "result": "Entailment.\n\nThe PRIMARY TRIAL RESULTS section reports the Objective Response Rate (ORR) for the Fulvestrant 250 mg and Fulvestrant 250 mg + Loading Dose arms, using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 to assess objective response. The SECONDARY TRIAL RESULTS section reports the Objective Response (OR) for Cohort B, also using RECIST version 1.0.\n\nAlthough the primary and secondary trials use the same outcome measurement (Objective Response), they use different definitions of complete response. The primary trial uses a best overall response of either complete response (CR) or partial response (PR) to define objective response, while the secondary trial uses complete response (CR) and partial response (PR) as assessed by RECIST version 1.0.\n\nTherefore, the statement that the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions, however they use different definitions of complete response, entails from the given trial information."}
{"id": "251a20d8-2555-4929-9d01-c02311bdc93f", "result": "Entailment.\n\nThe statement entails from the given trial information. The trial reports that 35 participants out of 50 (70%) in cohort 1 had disease progression or death, while 40 participants out of 49 (82%) in cohort 2 had disease progression or death. This indicates that a higher proportion of patients suffered disease progression or death in cohort 2 than in cohort 1."}
{"id": "dd2f3c3d-fa95-4fca-a3f0-795fd4f3abf1", "result": "Entailment.\n\nThe primary trial records the outcome measurement of LDex change, which is a measure of extracellular fluid accumulation, while the secondary trial records the outcome measurement of overall survival (OS), which is the time from the date of randomization to the date of death from any cause. These are different metrics and are not directly comparable. Therefore, the statement entails from the given trial information."}
{"id": "f0273b8c-460d-46fe-9c52-8ff4b08e439b", "result": "Entailment.\n\nThe primary trial's eligibility criteria state that women aged 18 years or older with newly diagnosed, infiltrating (invasive) HER2-neu-negative or HER2-neu-positive breast cancer are eligible. Both Eliane (56 years old) and Elizabeth (32 years old) meet this criterion, as they are both women with newly diagnosed breast cancer.\n\nTherefore, both Eliane and Elizabeth can be eligible for the primary trial, assuming they do not have any exclusion criteria, such as evidence of metastatic disease or previous systemic or local primary treatment."}
{"id": "bc2024fc-5b39-4fa6-badf-f034d6fe8bb8", "result": "Entailment.\n\nThe eligibility criteria for the primary trial state that patients must have a pathologically confirmed diagnosis of breast cancer with documented progressive disease. This means that patients must have evidence of disease progression, such as an increased tumor size or the appearance of new metastases, to be eligible for the trial.\n\nTherefore, the statement \"Breast cancer patients must have documented progressive disease to participate in the primary trial\" entails from the given trial information."}
{"id": "c2217d42-e90c-4ffe-b084-e653b9ace4d5", "result": "Contradiction.\n\nThe primary trial and the secondary trial do not record any cardiac or infection related adverse events, but they both record several instances of epilepsy. This statement is contradictory because the adverse events listed in the primary and secondary trials do not include epilepsy.\n\nThe primary trial lists two adverse events, neither of which is related to cardiac or infection, and both have a frequency of 0%. The secondary trial also lists two adverse events, neither of which is related to cardiac or infection, and both have a frequency of 0%. Therefore, the statement that the trials record several instances of epilepsy is not supported by the given information."}
{"id": "080da381-b5dd-46d3-99c4-18112da153c1", "result": "Entailment.\n\nThe statement \"There are less cases of Acute myocardial infarction, Cardiopulmonary failure, and Supraventricular tachycardia in cohort 1 of the secondary trial than in cohort 2 of the primary trial\" can be inferred from the given trial information.\n\nIn the primary trial, cohort 2 has 1 case of Acute myocardial infarction, 1 case of Cardiopulmonary failure, and 1 case of Supraventricular tachycardia, out of a total of 199 patients.\n\nIn the secondary trial, cohort 1 has 0 cases of Acute myocardial infarction, 0 cases of Cardiopulmonary failure, and 1 case of Supraventricular tachycardia, out of a total of 199 patients.\n\nTherefore, the statement is true, as there are indeed fewer cases of these adverse events in cohort 1 of the secondary trial compared to cohort 2 of the primary trial."}
{"id": "c100a7cd-e3a2-4901-a3e0-12336f769c7b", "result": "Contradiction.\n\nThe statement \"the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial reported 16\" is not accurate based on the given trial information.\n\nThe primary trial reported 1 case of Conjunctivitis in the Adverse Events 1 section, which corresponds to a frequency of 2.08% (1/48).\n\nThe secondary trial reported 1 case of Conjunctivitis in the Adverse Events 1 section, which corresponds to a frequency of 0.19% (1/519).\n\nTherefore, the statement is incorrect, as the secondary trial reported a lower frequency of Conjunctivitis compared to the primary trial."}
{"id": "ec1e269e-470d-43d9-8f23-8a19a5c96fcc", "result": "Contradiction.\n\nThe statement \"Anaemia was the most common adverse event in cohort 1 of the primary trial and tachycardia was the most common in cohort 2\" is not accurate based on the given trial information.\n\nAccording to the Adverse Events 1 section, the most common adverse event in cohort 1 of the primary trial was actually Thrombocytopenia, which occurred in 2/199 (1.01%) patients. Anaemia occurred in 7/199 (3.52%) patients, which was the second most common adverse event in this cohort.\n\nSimilarly, according to the Adverse Events 2 section, the most common adverse event in cohort 2 of the primary trial was actually Ventricular tachycardia, which occurred in 1/36 (2.78%) patients. Supraventricular tachycardia occurred in 1/36 (2.78%) patients, which was the second most common adverse event in this cohort.\n\nTherefore, the statement is incorrect, as Thrombocytopenia was the most common adverse event in cohort 1, and Ventricular tachycardia was the most common adverse event in cohort 2."}
{"id": "21611c2a-e6eb-4012-a209-9b6781e1f260", "result": "Contradiction.\n\nThe statement \"There is no adverse events section in the primary trial\" is not accurate based on the given trial information. The Adverse Events section of the primary trial is provided below, which shows that there are adverse events recorded in the trial. Therefore, the statement entails a contradiction."}
{"id": "d1b7105d-0b7d-4b10-92a7-d63243ff0629", "result": "Entailment.\n\nThe statement \"Patients with significantly low ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or younger\" is accurate based on the given trial information.\n\nThe primary trial excludes patients with a left ventricular function with resting ejection fraction < 50% (below upper limit of normal), indicating that patients with significantly low ejection fraction are not eligible for the primary trial.\n\nOn the other hand, the secondary trial does not have an explicit exclusion criterion related to ejection fraction. Instead, it focuses on premenopausal women 55 years of age or younger with regular menstrual cycles, and allows patients who are taking hormone replacement therapy (estrogen or progesterone) or tamoxifen or raloxifene, as long as they have stopped for at least 4 months prior to study entry. Therefore, patients with low ejection fraction who are 55 years of age or younger can still be eligible for the secondary trial."}
{"id": "7f3fe97e-68ee-470f-b06e-21cdddb67aa8", "result": "Sure, here's a numbered list of the inclusion and exclusion criteria for the secondary trial:\n\n\nInclusion Criteria:\n\n1. Patients with metastatic or advanced solid tumors\n2. Women with histologically or cytologically confirmed triple negative breast cancer\n3. Participants with histologically or cytologically confirmed pancreatic adenocarcinoma\n4. Patients with histologically or cytologically confirmed non-small cell lung cancer (NSCLC)\n\n5. Patients may have received prior chemotherapy\n6. Patients may have received radiation therapy\n7. Patients may have chronic stable disease\n8. Patients may have had a history of cancer treated without curative intent\n9. Patients may receive other investigational agents while on study\n\n\nExclusion Criteria:\n\n1. Active brain metastases or leptomeningeal metastases\n2. Any serious or uncontrolled medical disorder\n3. Prior malignancy within the previous 3 years\n4. History of arterial thromboembolic events, including transient ischemic attack (TIA), cerebrovascular event (CVA), unstable angina, or myocardial infarction (MI) within the past 6 months\n5. Patients with clinically significant peripheral arterial disease should be excluded\n6. Patients with a history of bleeding diathesis or coagulopathy\n7. Patients with a history of grade 3 or 4 allergic reactions to compounds of similar chemical or biological composition to cyclophosphamide (such as other alkylating agents) or methotrexate (such as other antimetabolites)\n8. Patients with large or rapidly accumulating pleural or abdominal effusions\n9. Patients with a history of abdominal fistula, GI perforation, or serious, non-healing wound, ulcer, or bone fracture within 6 months prior to initiating bevacizumab\n10. Patients with known HIV infection\n11. Patients may not be pregnant, expect to become pregnant, plan to conceive a child while on study, or breastfeeding\n12. Uncontrolled intercurrent illness\n\nNote that the exclusion criteria list is not exhaustive, and other protocol-defined inclusion/exclusion criteria may apply."}
{"id": "ce8464bd-951e-44aa-97d9-10b917b055ce", "result": "ENTAILMENT.\n\nThe statement suggests that there was a higher percentage of patients with slipped disks in cohort 2 (1.02%) compared to cohort 1 (0.00%), which is a significant difference. This is based on the adverse event data provided for the primary trial, which shows that 1 patient in cohort 2 (out of 98) experienced a slipped disk, while 0 patients in cohort 1 (out of 101) experienced this adverse event."}
{"id": "0131ebe3-746b-45a5-ba60-fdd326974fec", "result": "ENTAILMENT.\n\nThe primary trial and the secondary trial both use outcome measurements that are based on the Response Evaluation Criteria In Solid Tumors (RECIST) and the American Joint Committee on Cancer (AJCC) Staging System. The primary trial measures overall response (CR, PR, or SD) in the first 6 months, while the secondary trial measures pathological complete response (pCR) in the breast and axilla at the surgery visit (Weeks 14 to 19). Both trials use similar response criteria, including CR, PR, and SD, and both use the AJCC Staging System to define pCR. Therefore, the statement that the primary trial and the secondary trial use comparable outcome measurements entails from the given trial information."}
{"id": "b1dd7632-ed92-40a9-9293-bce68619c658", "result": "ENTAILMENT.\n\nThe primary trial eligibility criteria state that patients must have stage I-III cancer of the female breast. This means that patients with stage 4 cancer are excluded from the trial, as they do not meet the eligibility criteria. Only patients with stage 2 and 3 cancer can be eligible for the primary trial. Therefore, the statement entails from the given trial information."}
{"id": "45ccd2c8-6e02-4f0f-a370-eed18d26e6dc", "result": "ENTAILMENT.\n\nThe Intervention section of the primary trial describes the administration of Fulvestrant and Everolimus to the trial participants. Fulvestrant is administered intramuscularly (in the gluteus maximus) in a loading dose schedule, while Everolimus is administered orally. Therefore, the statement that the primary trial participants are administered Fulvestrant intramuscularly and Everolimus orally entails from the given trial information."}
{"id": "4a15ec5e-4904-4f01-a0a2-c51e83c8c070", "result": "ENTAILMENT.\n\nThe primary trial results section reports the severity of radiation dermatitis in the radiation treatment site for both the Curcumin C3 Complex cohort and the placebo cohort. The results are presented in terms of the mean and standard deviation of the Radiation Dermatitis Severity (RDS) scale scores for each cohort. Therefore, the statement entails from the given trial information."}
{"id": "b9e29ea8-6847-40d4-b5c3-81c496101695", "result": "ENTAILMENT.\n\nThe statement \"All patients in cohort 1 of the primary trial had a PFS of over 8.8 months, with the highest PFS being just under 10 months\" entails from the given trial information.\n\nThe primary trial results section reports the centrally assessed progression-free survival (PFS) for both the Neratinib Plus Capecitabine and Lapatinib Plus Capecitabine cohorts. The PFS is measured in months and is defined as the time interval from the date of randomization until the first date on which recurrence, progression, or death due to any cause is documented. The results show that the mean PFS for the Neratinib Plus Capecitabine cohort was 8.8 months (95% CI: 7.8-9.8), while the mean PFS for the Lapatinib Plus Capecitabine cohort was 6.6 months (95% CI: 5.9-7.4).\n\nSince the highest PFS reported in the Neratinib Plus Capecitabine cohort was 8.8 months, and all patients in this cohort had a PFS of over 8.8 months, it follows that the highest PFS in this cohort was indeed just under 10 months. Therefore, the statement entails from the given trial information."}
{"id": "2a2c16a7-f427-4fdb-8153-94aac304e4b8", "result": "ENTAILMENT.\n\nThe statement \"Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks, and patients receive the same types and dosages of medication throughout all 17 cycles\" entails from the given trial information.\n\nThe trial describes two cohorts, HER2+ TC and HER2+ C, both of which receive treatment for a total of 17 cycles, with each cycle lasting 3 weeks. The types and dosages of medications used in each cycle are the same for both cohorts, with the exception of trastuzumab, which is used in HER2+ TC but not in HER2+ C.\n\nTherefore, the statement entails from the given trial information, as both cohorts receive the same types and dosages of medication throughout all 17 cycles."}
{"id": "618a3ae1-b22c-4c35-86a6-190c1b5b5d21", "result": "ENTAILMENT.\n\nThe statement \"Patients must have a Life expectancy of at least 1 year to enroll in the primary trial\" entails from the given trial information.\n\nThe trial's inclusion criteria state that patients must have a life expectancy of at least 1 year to be eligible for the study. This means that patients who have a life expectancy of less than 1 year are not eligible to participate in the trial.\n\nTherefore, the statement entails from the given trial information, as it is a necessary condition for patients to have a life expectancy of at least 1 year in order to be eligible for the trial."}
{"id": "e62f5a3f-0091-4980-9822-db8f4dc2502a", "result": "CONTRADICTION.\n\nThe statement suggests that there is no difference in the severity of dermatitis between the Curcumin C3 Complex cohort and the placebo cohort, but the results provided in the trial information show that the mean severity of dermatitis for the Curcumin C3 Complex cohort (2.6 \u00b1 0.994) is lower than that of the placebo cohort (3.4 \u00b1 0.554). This difference is statistically significant, as the 95% confidence interval for the difference between the two means does not include zero (95% CI: -1.38, -0.47). Therefore, the statement does not entail from the given trial information."}
{"id": "4a41ac73-538a-43e5-b7ce-8c8e2d56286e", "result": "ENTAILMENT.\n\nThe secondary trial's exclusion criteria specify that patients who are currently receiving endocrine therapy are not eligible, unless they are receiving adjuvant therapy. This means that women who are currently undergoing endocrine therapy are excluded from the secondary trial, which entails that they are also excluded from the primary trial, as the primary trial's inclusion criteria state that patients must not have any known soy intolerance and must be willing to keep a dietary diary, which would not be possible if they are undergoing endocrine therapy. Therefore, the statement entails from the given trial information."}
{"id": "75a65913-5655-4377-b441-ecdd4dd75175", "result": "ENTAILMENT.\n\nThe eligibility criteria for the primary trial specify that patients must have stage I-III cancer of the female breast, and patients with a history of other invasive malignancies are eligible as long as they have completed treatment and are 5 years post-diagnosis. This means that patients with stage 4 cancer are not eligible for the primary trial, as they have a history of invasive breast cancer that has progressed beyond stage III. Therefore, the statement entails from the given trial information."}
{"id": "1329dec6-fb2c-4219-9db6-3fef9d94b316", "result": "ENTAILMENT.\n\nThe Adverse Events 1 table shows that in cohort 1, there were 2 cases of Left ventricular dysfunction and 1 case of Abdominal pain. This means that there were indeed 10 more cases of Left ventricular dysfunction than Abdominal pain in cohort 1, as stated. Therefore, the statement entails from the given trial information."}
{"id": "29b2fa29-5a76-4877-95bb-1a8de7973d33", "result": "ENTAILMENT.\n\nThe Adverse Events 1 table shows that 6 patients in cohort 1 of the primary trial suffered adverse events, which is consistent with the statement. Therefore, the statement entails from the given trial information."}
{"id": "7edba90d-076d-4f55-b9d6-a1765ceb48bd", "result": "CONTRADICTION.\n\nThe PRIMARY TRIAL INTERVENTION states that participants received intraductal administration of dextrose or dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD) prior to conventional surgery for breast cancer, which implies that they did not receive any medication by IV.\n\nHowever, the SECONDARY TRIAL INTERVENTION states that patients receive cetuximab IV over 60-120 minutes once a week, and that treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. This contradicts the statement that participants in both trials do not receive any medication by IV.\n\nTherefore, the statement does not entail from the given trial information."}
{"id": "ba9daeb9-796d-49ab-a30c-4d8acbdf4d37", "result": "CONTRADICTION.\n\nThe PRIMARY TRIAL RESULTS section states that the endpoint evaluated was the progression-free survival (PFS) of participants amongst the total evaluable population. The results show that 35 participants out of 50 (70%) in Arm 1 (Fulvestrant and Dasatinib) had disease progression or death, while 40 participants out of 49 (82%) in Arm 2 (Fulvestrant) had disease progression or death.\n\nThe statement suggests that patients receiving Fulvestrant were more likely to suffer disease progression or death than patients receiving Herceptin. However, the results show that the opposite is true, with a higher percentage of participants in Arm 2 (Fulvestrant) experiencing disease progression or death compared to Arm 1 (Fulvestrant and Dasatinib).\n\nTherefore, the statement does not entail from the given trial information, and it appears to be a contradiction."}
{"id": "1314146f-2869-4525-8034-7f732d238385", "result": "ENTAILMENT.\n\nThe Adverse Events sections of the primary trial show that the total number of patients experiencing adverse events was 340/1612 (21.09%) in Adverse Events 1 and 350/1623 (21.57%) in Adverse Events 2. However, none of the individual adverse events affected more than 100 patients.\n\nThe statement is entailed by the information provided in the Adverse Events sections, as none of the adverse events exceeded 100 patients. Therefore, the statement is true."}
{"id": "7c7418d2-32d7-4517-874b-eb3db24ea16a", "result": "ENTAILMENT.\n\nThe Inclusion Criteria of the primary trial specify that candidates must be over the age of 18, have a Karnofsky performance status index > 80%, and have adequate hepatic, renal, and heart functions, as well as adequate hematology levels. These criteria entail the statement.\n\nTherefore, the statement is true."}
{"id": "1f6a14ae-e22b-4b40-b389-217570dbf38e", "result": "ENTAILMENT.\n\nThe statement \"50% of cohort 2 patients in the primary trial suffered Dose Limiting Toxicities\" can be inferred from the given trial information.\n\nIn Results 2, the overall number of participants analyzed is 2, and the number of dose-limiting toxicities (DLTs) is 1. Therefore, the proportion of patients who suffered DLTs in cohort 2 is 1/2 = 50%.\n\nThis entails the statement."}
{"id": "5c1e360c-fd93-4dd4-b855-71ba416d34cb", "result": "ENTAILMENT.\n\nThe statement \"patients must be able to receive medication orally to participate in the primary trial\" entails from the given trial information. The Eligibility section specifies that patients must be able to swallow an oral medication, which means that they must be able to receive medication orally. Therefore, patients who are unable to receive medication orally would not be eligible for the trial."}
{"id": "c7a953b0-ac96-4e0a-9c1d-98cf8af2861d", "result": "ENTAILMENT.\n\nThe statement \"the primary trial and the secondary trial report the same types of adverse events\" entails from the given trial information. Both trials report adverse events related to gadolinium contrast agents, specifically, immediate or delayed hypersensitivity reactions. The fact that both trials report the same types of adverse events suggests that they are studying the same population and using the same methods, which supports the entailment of the statement."}
{"id": "48f516ff-abb4-4312-9b00-02f53fb16218", "result": "ENTAILMENT.\n\nThe statement \"under a quarter of the primary trial patients in the intervention arm experienced Pathologic Complete Response\" entails from the given trial information. The Results section reports that 26% of patients in the intervention arm experienced Pathologic Complete Response, which is less than a quarter but still a significant proportion of patients. Therefore, the statement is entailed by the given information."}
{"id": "978d19fc-e7f6-485e-b8bd-cfcde06441ab", "result": "ENTAILMENT.\n\nThe statement \"T1 N0 M0 patients are eligible for the primary trial\" entails from the given trial information. The eligibility criteria for the primary trial specify that patients with histologically confirmed stage I, II, or III breast cancer are eligible, and T1-3, N0-2, M0 disease is listed as one of the eligible disease characteristics. Additionally, the criteria specify that patients must have undergone prior total mastectomy or breast-conserving procedure (e.g., lumpectomy, quadrantectomy, or partial mastectomy with negative margins) with radiotherapy planned, which would include T1 N0 M0 patients. Therefore, the statement is entailed by the given information."}
{"id": "0a6d1b4c-244e-44e2-a229-62e4cbdfa979", "result": "ENTAILMENT.\n\nThe statement \"the results of the secondary trial and the primary trial are non-comparable\" entails from the given trial information. The primary trial is assessing the safety of external-beam PBI utilizing 40 Gy in ten daily fractions over two weeks in selected stages 0 and I female breast cancer patients, while the secondary trial is assessing the overall tumor response using RECIST criteria in patients treated with pemetrexed. The two trials have different objectives, patient populations, and outcome measures, making their results non-comparable."}
{"id": "9bcc31df-c1f6-4785-9235-f673213acf3a", "result": "ENTAILMENT.\n\nThe statement \"both the primary trial cohorts receive identical doses of Docetaxel\" entails from the given trial information. The Intervention section states that both Intervention 1 and Intervention 2 receive docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). Therefore, the statement is entailed by the given information."}
{"id": "63a0a9fc-80b9-450f-b2c6-7aee37ce26a9", "result": "ENTAILMENT.\n\nThe statement \"neither of the cohorts in the primary trial are required to undergo surgery or receive any oral medication as part of the intervention\" entails from the given trial information. The Intervention section describes the two cohorts, Intervention 1 and Intervention 2, and neither of them involve surgery or oral medication as part of the intervention. Intervention 1 involves taking a calcitriol pill once per week, while Intervention 2 involves exercise consisting of progressive walking and resistance band training, with an additional calcitriol pill taken once per week. Therefore, the statement is entailed by the given information."}
{"id": "75cf4ec2-9f2b-4d5b-8772-af247eaca07b", "result": "ENTAILMENT.\n\nThe statement \"Patients with histologically confirmed breast cancer stage I-III are not eligible for the primary trial\" entails from the given trial information. The trial specifically states that patients must have metastatic (stage IV) disease to be eligible, and patients with stage I-III disease are not eligible. Therefore, the statement is entailed by the given information."}
{"id": "553f00ea-5197-4233-b1e0-e5727856b599", "result": "CONTRADICTION.\n\nThe statement \"no cardiac or bowel-related adverse events were recorded in the primary trial\" contradicts the information provided in the Adverse Events section of the primary trial. The section lists \"Diarrhea\" as an adverse event, which is a bowel-related adverse event. Therefore, the statement is contradicted by the given information."}
{"id": "57b2ae97-0d1d-4d5d-bc4b-109e8e5acb32", "result": "ENTAILMENT.\n\nThe statement \"There were more cases of mental health disorders, PLEUROPERICARDITIS, ATRIAL THROMBOSIS, and Anemia in the secondary trial than in the primary trial\" entails from the given trial information.\n\nThe primary trial did not report any adverse events, while the secondary trial reported several adverse events, including Anemia, Febrile neutropenia, Eye disorders - Other, Visual disturbance, Abdominal pain, Constipation, Nausea, Fever, Pain, Skin infection, Alkaline phosphatase increased, and Aspartate aminotransferase increased.\n\nTherefore, the statement is entailed by the given information, as there were indeed more cases of adverse events in the secondary trial than in the primary trial."}
{"id": "215a5c4a-d90c-4500-8284-0679ce311734", "result": "ENTAILMENT.\n\nThe statement \"patients must have HER2- breast cancer to participate in the primary trial\" entails from the given trial information. The trial's inclusion criteria specify that patients must have ErbB2(HER2)overexpressing breast cancer, which means that HER2- breast cancer is not eligible for the trial."}
{"id": "e9a4bd91-f58b-4234-9037-75e0699d1bbd", "result": "CONTRADICTION.\n\nThe statement \"the primary trial participants receive less than 300mg/m^2 doses of Pralatrexate\" contradicts the information provided in the Intervention section of the primary trial. The Intervention section states that the participants receive a dose of 190 mg/m^2 of Pralatrexate for 2 to 4 weeks, which is clearly more than 300mg/m^2."}
{"id": "7d52734c-0801-413d-9ae2-d190b972cde5", "result": "ENTAILMENT.\n\nThe statement \"The results from the secondary trial and the primary trial can be compared by changing the units from days to months\" entails from the given trial information.\n\nThe primary trial reports the results of the intervention in terms of the number of participants with a complete pathologic response, which is measured at 8 weeks. The secondary trial reports the results of the intervention in terms of the change in Masood score, which is measured at 6 months.\n\nTo compare the results of the two trials, we need to convert the time frame of the secondary trial from months to days. There are 30 days in a month, so we can convert 6 months to 180 days (6 x 30).\n\nNow, we can compare the results of the two trials by looking at the number of participants with a complete pathologic response in the primary trial (13) and the change in Masood score in the secondary trial (mean = -1.1, standard deviation = 1.9).\n\nIt's important to note that the two trials have different outcome measures, so a direct comparison of the results may not be entirely appropriate. However, we can still compare the overall trend and direction of the results to get an idea of how the interventions performed in each trial."}
{"id": "5de9caeb-9dd5-4535-8fe3-289450d9c626", "result": "ENTAILMENT.\n\nThe statement \"the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher percentage of patients with CNS Metastases than the Lapatinib Plus Capecitabine group\" entails from the given trial information.\n\nThe primary trial results provide the number of participants with central nervous system (CNS) metastases as the site of first relapse in both the Lapatinib Plus Capecitabine and Trastuzumab Plus Capecitabine groups. The results show that 8 participants (out of 251) in the Lapatinib Plus Capecitabine group had CNS metastases, while 12 participants (out of 250) in the Trastuzumab Plus Capecitabine group had CNS metastases.\n\nTherefore, the proportion of participants with CNS metastases in the Trastuzumab Plus Capecitabine group (12/250 = 0.048) is higher than the proportion of participants with CNS metastases in the Lapatinib Plus Capecitabine group (8/251 = 0.032).\n\nThis difference in the proportion of participants with CNS metastases between the two groups is statistically significant, as the 95% confidence interval for the difference in proportions does not include zero (0.016 < 0.048 - 0.032 < 0.072). Therefore, the statement entails from the given trial information."}
{"id": "bebfc78e-b35f-4677-8342-9567a7e795a1", "result": "ENTAILMENT.\n\nThe statement \"There is one case of Diarrhea in the secondary trial and none in the primary trial\" entails from the given trial information.\n\nThe primary trial reports adverse events for 373 participants, and the secondary trial reports adverse events for 93 participants. The primary trial does not report any cases of diarrhea, while the secondary trial reports one case of diarrhea.\n\nTherefore, the statement is true, and the difference in the incidence of diarrhea between the two trials is statistically significant (p < 0.05), as the 95% confidence interval for the difference in proportions does not include zero (0.00 < 1.08 < 0.17)."}
{"id": "faa65e54-aa04-4595-8dae-05cf00b4c887", "result": "ENTAILMENT.\n\nThe statement \"Only cohort 1 patients of the primary trial are administered Ipatasertib\" entails from the given trial information.\n\nThe primary trial describes two interventions: Intervention 1, which involves the administration of ipatasertib and paclitaxel, and Intervention 2, which involves the administration of a placebo (matching to ipatasertib) and paclitaxel. The trial specifies that participants received ipatasertib orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel IV infusion every week (QW) for 3 cycles (12 total doses).\n\nTherefore, it can be inferred that only participants in Intervention 1, which includes cohort 1 patients, received ipatasertib. This means that the statement \"Only cohort 1 patients of the primary trial are administered Ipatasertib\" entails from the given trial information."}
{"id": "751fd763-89fa-4d52-8bda-f09b490a5e78", "result": "ENTAILMENT.\n\nThe statement \"there were no recorded deaths in the primary trial cohorts\" entails from the given trial information.\n\nThe primary trial reports the results of the outcome measurement \"Patients Event-free at 12 Months\" for both the Fulvestrant + Anastrozole and Anastrozole arms. The measure type is \"Number\" and the unit of measure is \"Participants.\" The results show that 6 participants in the Fulvestrant + Anastrozole arm and 7 participants in the Anastrozole arm were event-free at 12 months.\n\nSince the outcome measurement includes death (from any cause) as one of the events, the absence of any recorded deaths in both arms implies that there were no deaths in the primary trial cohorts. Therefore, the statement \"there were no recorded deaths in the primary trial cohorts\" entails from the given trial information."}
{"id": "c40fdf91-9f81-454a-bba9-ec5c950cef6e", "result": "ENTAILMENT.\n\nThe statement \"One patient cohort in the primary trial received a placebo intervention\" entails from the given trial information.\n\nThe primary trial describes two interventions: Intervention 1, which involves the administration of lapatinib 1500 mg, and Intervention 2, which involves the administration of a placebo. The trial specifies that participants received either lapatinib or placebo orally once daily, and that treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer, withdrawal from study treatment due to unacceptable toxicity, or consent withdrawal.\n\nTherefore, it can be inferred that one patient cohort in the primary trial received a placebo intervention, as the trial included a placebo arm. This means that the statement \"One patient cohort in the primary trial received a placebo intervention\" entails from the given trial information."}
{"id": "31105b43-832b-48bc-a78d-ee90c155ca44", "result": "ENTAILMENT.\n\nThe statement \"Presence of hot flashes for 30 days prior to study registration is required for all patients that want to participate in the primary trial, but not necessary for entry to the secondary trial\" entails from the given trial information.\n\nThe primary trial specifies that patients must have had hot flashes for 30 days prior to study registration to be eligible for the trial. On the other hand, the secondary trial does not mention anything about hot flashes or their duration as an inclusion or exclusion criterion. Therefore, it can be inferred that presence of hot flashes for 30 days prior to study registration is not necessary for entry to the secondary trial. This means that the statement \"Presence of hot flashes for 30 days prior to study registration is required for all patients that want to participate in the primary trial, but not necessary for entry to the secondary trial\" entails from the given trial information."}
{"id": "49ba06b2-576d-4db2-80b6-51673416f2ba", "result": "ENTAILMENT.\n\nThe statement \"the primary trial and the secondary trial measure the Percent Change in Net Influx Constant (Ki) by FLT PET in their patient cohorts\" entails from the given trial information.\n\nThe primary trial's Results section mentions that the study measures the percent change in Ki by FLT PET, and the secondary trial's Results section also mentions that the study measures the Percent Change in Net Influx Constant (Ki) by FLT PET. Therefore, both trials measure the same outcome, which is the change in Ki using FLT PET. This means that the statement \"the primary trial and the secondary trial measure the Percent Change in Net Influx Constant (Ki) by FLT PET in their patient cohorts\" entails from the given trial information."}
{"id": "3cb71095-8e01-40dc-bbf5-eeffed55f354", "result": "CONTRADICTION.\n\nThe statement \"Patients with histologically confirmed breast cancer stage I-IV are not eligible for the primary trial\" contradicts the eligibility criteria listed in the primary trial's Eligibility section. The trial's eligibility criteria state that patients with metastatic (stage IV) disease are eligible, and do not mention anything about patients with earlier stages of breast cancer (stage I-III) being excluded. In fact, the inclusion criteria specifically state that patients with histologically documented (either primary or metastatic site) breast cancer that is ER-negative, PR-negative, and HER-2 nonoverexpressing by immunohistochemistry (0,1) or non-gene amplified by FISH performed upon the primary tumor or metastatic lesion are eligible. Therefore, patients with earlier stages of breast cancer may be eligible for the primary trial if they meet the other eligibility criteria."}
{"id": "09fc4356-6154-427e-b710-ed5df6470aff", "result": "CONTRADICTION.\n\nThe statement \"50% of cohort 2 patients in the primary trial suffered Keratitis\" is not supported by the given trial information. The Results section only reports the number of dose-limiting toxicities (DLTs) observed in each arm of the trial, and does not provide information on the incidence of specific adverse events (AEs) in each cohort.\n\nAccording to the Results section, there were 2 DLTs in cohort 2 (AZD8931 120 mg bd), which consisted of 1 case of diarrhea and 1 case of oesophagitis. There is no mention of Keratitis or any other specific AE occurring in 50% of cohort 2 patients. Therefore, the statement \"50% of cohort 2 patients in the primary trial suffered Keratitis\" does not entail from the given trial information and is considered a contradiction."}
{"id": "446f3c69-0de5-475c-a8e2-ff40ece90672", "result": "ENTAILMENT.\n\nThe statement \"Only patients with HER2+ve breast cancer are eligible for the primary trial\" entails from the given trial information. The Eligibility section specifically states that one of the Inclusion Criteria is \"HER-2 positive BC as defined by an immunohistochemistry score of 3 or gene amplified by in-situ hybridization as defined by a ratio of greater than or equal to (>=) 2.0 for the number of HER2 gene copies to the number of chromosome 17 copies.\" This means that only patients with HER2-positive breast cancer are eligible for the trial."}
{"id": "cdadcb0a-20c5-47f7-a63a-39f5c6f26ae2", "result": "ENTAILMENT.\n\nThe statement \"the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer 0 side effects\" entails from the given trial information. The Results section shows the incidence of dose-limiting toxicity (DLT) in patients treated with Neratinib in combination with Paclitaxel. The DLT incidence is reported as 0% for both the 160 mg and 240 mg doses of Neratinib. This means that none of the patients treated with Neratinib in combination with Paclitaxel experienced DLT, which implies that they did not suffer any side effects. Therefore, the statement entails from the given trial information."}
{"id": "f0e845f9-8991-45b5-a520-51e934756f7a", "result": "ENTAILMENT.\n\nThe statement \"The primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure\" entails from the given trial information. The primary trial intervention describes Letrozole, a drug that is taken orally once daily, while the secondary trial intervention describes Sentinel Lymph Node Biopsy, a medical procedure. Therefore, the statement accurately summarizes the differences between the two trial interventions."}
{"id": "a0065d58-e03b-4dd0-9c81-cbbf651a6d45", "result": "ENTAILMENT.\n\nThe secondary trial eligibility criteria include patients with ErbB2(HER2) overexpressing breast cancer, brain lesion(s) that are progressing, and prior treatment of brain metastases with Whole Brain Radiotherapy (WBR) and/or Stereotactic Radiosurgery (SRS). Additionally, patients must have adequate kidney and liver function, adequate bone marrow function, and be able to swallow an oral medication.\n\nThe primary trial eligibility criteria include patients with invasive adenocarcinoma of the breast confirmed at MSKCC, evidence of recurrent or progressive locally advanced or metastatic breast cancer, and presence of at least one measurable metastatic lesion. Patients must also have adequate organ function, including kidney and liver function, and be able to swallow an oral medication.\n\nSince the secondary trial eligibility criteria are a subset of the primary trial eligibility criteria, any patient eligible for the secondary trial will also be eligible for the primary trial. Therefore, the statement \"any patient eligible for the secondary trial will also be eligible for the primary trial\" entails from the given trial information."}
{"id": "b2cdbcb8-de26-4a44-8a94-dd68c13f7e41", "result": "Contradiction.\n\nThe PRIMARY TRIAL ELIGIBILITY section states that an ECOG score of 0 or 1 is required for eligibility, but it does not mention anything about an ECOG score > 2 being necessary. Therefore, the statement \"ECOG score > 2 is necessary to be eligible for the primary trial\" does not entail from the given trial information."}
{"id": "973f090a-8967-4d75-bb8e-6166c868337c", "result": "Contradiction.\n\nThe PRIMARY TRIAL INTERVENTION section states that both cohorts (INTERVENTION 1 and INTERVENTION 2) receive the same dose of paclitaxel (IV infusion every week for 3 cycles, totaling 12 doses), and that the only difference between the two cohorts is the administration of ipatasertib (orally daily on Days 1-21 of each 28-day cycle for 3 cycles) in INTERVENTION 1, versus placebo (matching to ipatasertib) in INTERVENTION 2. Therefore, the statement \"cohort 1 patients of the primary trial are administered higher doses of Ipatasertib and Placebo than cohort 2 patients\" does not entail from the given trial information."}
{"id": "79ca2ee8-6c9c-40e6-a87c-925b50d3d3d2", "result": "Contradiction.\n\nThe PRIMARY TRIAL ELIGIBILITY section does not mention any requirements related to visible carcinomas in the stomach and neck areas. In fact, the inclusion criteria for both Phase 1 and Phase 2 focus on breast cancer, specifically invasive breast cancer or ductal carcinoma in situ, and require that the tumor be visible and enhance on breast MRI imaging. There is no mention of any other cancer locations or requirements related to carcinomas in the stomach and neck areas. Therefore, the statement \"Patients must have several visible carcinomas in the stomach and neck areas to be included in the primary trial\" does not entail from the given trial information."}
{"id": "1d1f57f8-85f7-448c-a4bb-15957da568fd", "result": "Entailment.\n\nThe statement \"the primary trial intervention protocol will continue until patients achieve complete response or suffer disease progression\" entails from the given trial information. The PRIMARY TRIAL INTERVENTION section states that INTERVENTION 1 involves administering pemetrexed at a dose of 600 mg/m2 intravenously every 14 days until complete response or disease progression. This implies that the intervention will continue until one of the two conditions is met: complete response or disease progression. Therefore, the statement accurately reflects the information provided in the PRIMARY TRIAL INTERVENTION section."}
{"id": "9f7d476e-9db3-4c00-abe6-4c2f0160470a", "result": "Contradiction.\n\nThe PRIMARY TRIAL RESULTS section states that the overall number of participants analyzed in the intervention arm was 32, and the percentage of participants who experienced Pathologic Complete Response was 26. This means that more than 30% of the patients in the intervention arm experienced Pathologic Complete Response, contradicting the statement that under 30% of the patients in the intervention arm experienced this outcome."}
{"id": "a5e388b9-da3c-437e-a6af-7ba76ad8bf1d", "result": "Entailment.\n\nThe statement \"both the primary trial cohorts receive identical doses of Docetaxel, with cohort 1 also receiving 100 mg/m^2 of Placebo\" entails from the given trial information. The PRIMARY TRIAL INTERVENTION section states that both interventions, INTERVENTION 1 and INTERVENTION 2, involve administering docetaxel at a dose of 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). Additionally, INTERVENTION 1 includes the administration of placebo to bevacizumab intravenously on Day 1 of each 3 week cycle, while INTERVENTION 2 includes the administration of bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3 week cycle. Therefore, the statement accurately reflects the information provided in the PRIMARY TRIAL INTERVENTION section."}
{"id": "3adcc8fc-b76b-407a-a006-729a13f571fb", "result": "Contradiction.\n\nThe PRIMARY TRIAL INTERVENTION section describes two different interventions for the two cohorts:\n\n* INTERVENTION 1: Nivolumab + Daratumumab (TNBC) for triple-negative breast cancer (TNBC)\n* INTERVENTION 2: Nivolumab + Daratumumab (NSCLC) for non-small cell lung cancer (NSCLC)\n\nThe statement suggests that both cohorts receive the same intervention, but the type of cancer diagnosis is different. However, the PRIMARY TRIAL INTERVENTION section shows that the interventions themselves are different, with different drugs and dosages used for each cohort. Therefore, the statement does not entail from the given trial information and is considered a contradiction."}
{"id": "68379456-775b-463b-bfdb-d8aa42c9124b", "result": "Entailment.\n\nThe PRIMARY TRIAL ELIGIBILITY section lists several inclusion criteria that must be met for patients to be eligible for the trial, including:\n\n* Females with histologic or cytologic diagnosis of advanced breast cancer\n* Performance status of 0 to 2 on the ECOG performance status scale\n* One prior chemotherapy containing anthracyclines or taxanes as (neo)adjuvant or palliative 1st-line treatment\n* Prior radiation therapy is allowed to less than 25% of the bone marrow\n* At least one uni-dimensionally measurable lesion meeting RECIST criteria\n* Antitumoral hormonal treatment must be discontinued prior to enrollment\n* Estimated life expectancy of at least 3 months\n* Participant compliance and geographic proximity that allow adequate follow-up\n* Adequate organ function\n* Female participants of childbearing potential must test negative for pregnancy within 7 days of enrollment and agree to use a reliable method of birth control during and for 6 months following the last dose of study drug\n* Participants must sign an informed consent document\n\nThe SECONDARY TRIAL ELIGIBILITY section lists the following inclusion criteria:\n\n* Confirmed hormone receptor positive advanced breast cancer, postmenopausal women\n\nThe statement \"Patients must be female and have confirmed advanced breast cancer to be eligible for the secondary trial and the primary trial\" entails from the given trial information because both trials require female patients with advanced breast cancer to be eligible. The primary trial includes additional inclusion criteria related to prior treatment, performance status, and measurable lesions, while the secondary trial includes an additional inclusion criterion related to hormone receptor status. Therefore, the statement is entailed and is a correct representation of the eligibility criteria for both trials."}
{"id": "5d0ccb93-71ec-4079-92c6-d7cbf951a7bb", "result": "The statement \"Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial\" does not entail from the given trial information.\n\nThe PRIMARY TRIAL ELIGIBILITY section does not mention anything about endocrine therapy, so it is not clear that women currently undergoing endocrine therapy are excluded from the primary trial.\n\nThe SECONDARY TRIAL ELIGIBILITY section does mention that patients with metastatic triple negative breast cancer (TNBC) are eligible for treatment with paclitaxel, regardless of their hormone receptor status. However, it also states that patients must be newly diagnosed metastatic or must have relapsed following a prior (neo)adjuvant chemotherapy regimen, and that patients who have received prior therapy for metastatic TNBC are excluded. It does not explicitly state that women currently undergoing endocrine therapy are excluded.\n\nTherefore, based on the information provided, it is not clear that women currently undergoing endocrine therapy are excluded from either trial."}
{"id": "f04d9695-81b8-4d70-877b-59caddf901bd", "result": "The statement \"Between the secondary trial and the primary trial, all the recorded cases of Dyspnea occurred in cohort 1 of the secondary trial\" does not entail from the given trial information.\n\nThe PRIMARY TRIAL ADVERSE EVENTS section does not mention Dyspnea as an adverse event. The SECONDARY TRIAL ADVERSE EVENTS section lists Dyspnea as an adverse event in cohort 1, but it does not provide information about the frequency or distribution of Dyspnea between the primary and secondary trials. Therefore, it cannot be inferred that all recorded cases of Dyspnea occurred in cohort 1 of the secondary trial.\n\nIn fact, the information provided suggests that there were no cases of Dyspnea in the primary trial, and that all recorded cases of Dyspnea occurred in the secondary trial. Therefore, the statement \"Between the secondary trial and the primary trial, all the recorded cases of Dyspnea occurred in cohort 1 of the secondary trial\" actually contradicts the information provided in the trials."}
{"id": "f42e1874-343a-43ed-bb0c-884509c4793c", "result": "The statement \"the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures Number of Participants With Disease Progression (PD) or Death\" entails from the given trial information.\n\nThe PRIMARY TRIAL RESULTS section describes the outcome measurement as the \"Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST])\", which suggests that the primary trial is measuring the proportion of participants who experience an objective response to treatment.\n\nThe SECONDARY TRIAL RESULTS section describes the outcome measurement as \"Progression Free Survival\", which is defined as the period from randomization until the first observation of lesion progression or death from any cause. The section also mentions that disease progression is defined as PD according to RECIST Ver. 1.1. This suggests that the secondary trial is measuring the length of time during which participants remain free of disease progression or death.\n\nTherefore, the statement accurately summarizes the difference between the primary and secondary trials in terms of the outcome measures used. The primary trial focuses on objective response rate, while the secondary trial focuses on progression-free survival."}
{"id": "30483d7e-7703-459c-bd10-e2bd259c2a4f", "result": "The statement \"there were two types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial\" contradicts the information provided in the PRIMARY TRIAL ADVERSE EVENTS section.\n\nThe section lists Thrombocytopenia, Anaemia, Febrile neutropenia, Leukopenia, Neutropenia, Pericardial effusion, Tachycardia, Nausea, Vomiting, Constipation, and Abdominal pain as adverse events that occurred in cohort 1 of the primary trial. It also specifies the number of patients who experienced each adverse event, and none of the events had a frequency of 0%.\n\nTherefore, the statement is incorrect, as there were adverse events that affected patients in cohort 1 of the primary trial."}
{"id": "7cde9a22-a91f-4feb-892d-7cbd35f96a27", "result": "The statement \"the primary trial reports the changes in tumor size for patients in its cohorts\" entails from the given trial information.\n\nThe PRIMARY TRIAL RESULTS section reports the outcome measurement of change in tumor size (CTS) from baseline to the end of Cycle 2, which is calculated as the log ratio of tumor size at Cycle 2 to tumor size at baseline. The results are presented for each arm/group, including the mean and standard deviation of the log ratio.\n\nTherefore, the statement is entailed, as the primary trial does report the changes in tumor size for patients in its cohorts."}
{"id": "16c29502-4683-4087-9410-ff1b786556f5", "result": "The statement \"The least common adverse event in the primary trial was Constipation\" contradicts the information provided in the PRIMARY TRIAL ADVERSE EVENTS section.\n\nAccording to the table, Constipation occurred in 1/41 (2.44%) of patients, which is not the least common adverse event. The least common adverse event listed in the table is actually Anemia, which occurred in 1/41 (2.44%) of patients.\n\nTherefore, the statement is incorrect, and the correct answer is contradiction."}
{"id": "5c975af8-6b7f-4a5d-b4a6-257c76763ce9", "result": "The statement \"There are more cases of Acute myocardial infarction, Cardiopulmonary failure, and Supraventricular tachycardia in cohort 1 of the secondary trial than in the entire patient cohort of the primary trial\" contradicts the information provided in the Adverse Events sections of both trials.\n\nIn the primary trial, there are no reported cases of Acute myocardial infarction, Cardiopulmonary failure, or Supraventricular tachycardia. In contrast, the secondary trial reports 1 case of Acute myocardial infarction, 1 case of Cardiopulmonary failure, and 1 case of Supraventricular tachycardia in cohort 1.\n\nTherefore, the statement is incorrect, and the correct answer is contradiction."}
{"id": "1c4e3fe3-b5fe-4ea3-8d9e-0ce1502080e7", "result": "The statement \"There were more total AEs in cohort 1 of the primary trial than cohort 2\" entails from the given trial information.\n\nAccording to the Adverse Events section, cohort 1 had a total of 13 AEs (13/61, or 21.31%), while cohort 2 had a total of 12 AEs (12/60, or 20.00%). This means that cohort 1 had a higher incidence of AEs than cohort 2.\n\nTherefore, the statement is entailed, and the answer is entailment."}
{"id": "8e91e404-086e-4063-8d54-83d1b8ebd969", "result": "The statement \"over 1/6 patients in cohort 1 of the primary trial suffered adverse events\" entails from the given trial information.\n\nAccording to the Adverse Events section, there were 6 adverse events in cohort 1, out of a total of 67 patients (6/67, or 8.96%). This means that more than 1/6 patients in cohort 1 (i.e., over 16.67%) suffered adverse events.\n\nTherefore, the statement is entailed, and the answer is entailment."}
{"id": "b8322b23-a4f6-4cba-9761-be826b509de7", "result": "The statement \"There were more cases of Eye disorders, Abdominal pain, Febrile neutropenia, and Anemia in the secondary trial than in the primary trial\" contradicts the information provided in the Adverse Events sections of both trials.\n\nIn the primary trial, there were no reported cases of Eye disorders, Abdominal pain, Febrile neutropenia, or Anemia. In contrast, the secondary trial reported 1 case of Eye disorders - Other, Visual disturbance, 1 case of Febrile neutropenia, 1 case of Abdominal pain, and 2 cases of Anemia.\n\nTherefore, the statement is incorrect, and the answer is contradiction."}
{"id": "4519d1cf-7f78-4aa8-85d6-ac94f7eb75a3", "result": "The statement \"There is only one case of Diarrhea in the secondary trial and over 14 different types of AEs recorded in the primary trial cohorts\" entails from the given trial information.\n\nThe primary trial reports 14 different types of adverse events (AEs) in the Adverse Events sections, including neutropenia, febrile neutropenia, leukopenia, anemia, lymphadenopathy, cardiac failure, atrial fibrillation, pericardial effusion, cardiac failure congestive, and cardiomyopathy. In contrast, the secondary trial reports only one case of diarrhea in the Adverse Events section.\n\nTherefore, the statement is entailed, and the answer is entailment."}
{"id": "4b97a844-8d52-48bb-8eda-ca205268f016", "result": "The statement \"Patients must have a Life expectancy of 75+ years to enroll in the primary trial\" contradicts the information provided in the Eligibility section of the primary trial.\n\nThe Eligibility section states that patients must have a Life expectancy of 1 year to enroll in the trial. This means that patients with a life expectancy of less than 1 year are not eligible to participate in the trial. Therefore, the statement that patients must have a life expectancy of 75+ years to enroll in the primary trial is incorrect.\n\nThe answer is contradiction."}
{"id": "2a03c17f-3afe-40f1-a0db-4b876ee8c700", "result": "The statement \"the primary trial and the secondary trial have non-comparable outcome measurements for their results\" entails from the given trial information.\n\nThe primary trial measures the percent change in net influx constant (Ki) by FLT PET, while the secondary trial measures progression-free survival (PFS) as assessed by investigator using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. These two outcome measurements are not comparable, as they measure different aspects of the treatment's effectiveness. The primary trial measures the change in a specific physiological parameter (Ki) in response to the treatment, while the secondary trial measures the duration of time until disease progression or death.\n\nTherefore, the answer is entailment."}
{"id": "3ba42f68-a643-4d10-afd0-cbb358d05a6f", "result": "The statement \"All patients in the primary trial receive higher doses of Paclitaxel than patients in the secondary trial\" contradicts the information provided in the Intervention sections of the primary and secondary trials.\n\nThe primary trial describes two interventions: INTERVENTION 1: BKM120 and Paclitaxel, and INTERVENTION 2: Placebo and Paclitaxel. Both interventions involve the use of paclitaxel, but the dosage is not specified.\n\nThe secondary trial describes one intervention: Active Breathing Coordinator. This intervention does not involve the use of paclitaxel.\n\nTherefore, the statement that all patients in the primary trial receive higher doses of paclitaxel than patients in the secondary trial is not supported by the information provided. The answer is contradiction."}
{"id": "0a079cca-abde-42cf-9cec-a76e7a380e14", "result": "The statement \"neither of the cohorts in the primary trial are required to undergo surgery as part of the intervention\" entails from the given trial information.\n\nThe intervention section of the primary trial describes two arms: INTERVENTION 1: No Exercise, and INTERVENTION 2: Exercise. Neither of these arms involves surgery as part of the intervention. The No Exercise arm involves taking a calcitriol pill once per week, while the Exercise arm involves exercise consisting of progressive walking and resistance band training, but neither arm involves surgery.\n\nTherefore, the statement is entailed by the given trial information. The answer is entailment."}
{"id": "9c033072-5f94-4d79-af47-126d531f0d6e", "result": "The statement \"There are more cases of Holocraneal cephale and Catheter-related infections in the primary trial than in the secondary trial\" contradicts the information provided in the Adverse Events sections of the primary and secondary trials.\n\nThe primary trial reports 1 case of Holocraneal cephale (1/12, 8.33%) and 2 cases of Catheter-related infections (2/12, 16.67%).\n\nThe secondary trial reports 0 cases of Holocraneal cephale and 0 cases of Catheter-related infections.\n\nTherefore, the statement is contradicted by the information provided. The answer is contradiction."}
{"id": "a52b2d4f-0b06-4960-a9c3-88cb92df0980", "result": "The statement \"the primary trial participants receive Capecitabine less often than they receive Lapatinib\" contradicts the information provided in the Intervention section of the primary trial.\n\nAccording to the Intervention section, participants received Lapatinib once daily and Capecitabine twice daily on the first day through the fourteenth day of each 21-day cycle. This means that participants received Capecitabine more frequently than Lapatinib.\n\nTherefore, the statement is contradicted by the information provided. The answer is contradiction."}
{"id": "a792bbac-0e8a-4bf7-9cc5-56fad481e2fb", "result": "The statement \"Eliane is a 56 year old woman, and Alex is a 32 year old man, both Eliane and Alex can both be eligible for the primary trial\" contradicts the information provided in the Eligibility section of the primary trial.\n\nThe Inclusion Criteria specify that participants must be women aged 18 years or older, and the Exclusion Criteria specify that participants with evidence of metastatic disease, except ipsilateral (same side) axillary lymph nodes, are not eligible. Therefore, Eliane, who is a 56 year old woman, would be eligible for the primary trial if she meets the other Inclusion Criteria.\n\nHowever, Alex, who is a 32 year old man, would not be eligible for the primary trial because the Inclusion Criteria specify that participants must be women.\n\nTherefore, the statement is contradicted by the information provided. The answer is contradiction."}
{"id": "1842904b-5371-49ee-b6f4-8831b879098b", "result": "The statement \"Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting more than 5% of patients\" entails from the given trial information.\n\nAccording to the Adverse Events section, Febrile Neutropenia occurred in 3/56 patients (5.36%), which is the highest frequency of any adverse event reported in the trial. Therefore, the statement is entailed by the information provided. The answer is entailment."}
{"id": "324562e6-2b61-4a07-b937-86f99689f2d5", "result": "The statement \"Diarrhoea is the most common adverse event in the primary trial, and Anaemia is the most common in the secondary trial\" entails from the given trial information.\n\nAccording to the Adverse Events sections of the primary and secondary trials, the most common adverse events in each trial are as follows:\n\nPrimary trial:\n\n* Diarrhoea (5/65, 7.69%)\n\nSecondary trial:\n\n* Anaemia (6/472, 1.27%)\n\nTherefore, the statement is entailed by the information provided. The answer is entailment."}
{"id": "74e376d7-5713-43f3-93f1-9608059c9547", "result": "The statement \"neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients, in fact over 86% of patients receiving the Docetaxel Then Liposomal Doxorubicin intervention suffered fatal complications\" contradicts the information provided in the PRIMARY TRIAL RESULTS section.\n\nAccording to the results presented, the Overall Response Rate (ORR) for the Arm A - Liposomal Doxorubicin Then Docetaxel intervention was 28 (16 to 42)%, which is higher than 40%. Similarly, the ORR for the Arm B - Docetaxel Then Liposomal Doxorubicin intervention was 31 (18 to 45)%, which is also higher than 40%.\n\nAdditionally, the statement suggests that over 86% of patients receiving the Docetaxel Then Liposomal Doxorubicin intervention suffered fatal complications, which is not supported by the information provided. The results do not mention any fatal complications occurring in either arm of the trial.\n\nTherefore, the statement contradicts the information provided in the PRIMARY TRIAL RESULTS section. The answer is contradiction."}
{"id": "0e609fad-9a28-4fb6-90b6-32a731e3b02c", "result": "ENTAILMENT.\n\nThe primary trial reports the objective response rate (ORR) as a percentage of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria, while the secondary trial reports the proportion of sentinel lymph nodes (SLNs) flagged by the two methods (Tc and ICG) as a percentage. Although the units of measure are different (participants vs. sentinel lymph nodes), the results can still be compared as proportions. Therefore, the statement entails from the given trial information."}
{"id": "236780db-9e59-4dc9-8da0-e786287011cf", "result": "CONTRADICTION.\n\nThe statement suggests that the primary trial intervention protocol lasts a total of 14 days, but the information provided in the intervention section of the primary trial indicates that the intervention lasts until complete response or disease progression, which means that the duration of the intervention is not fixed and can vary depending on the individual patient's response to the treatment. Therefore, the statement does not entail from the given trial information."}
{"id": "6d621974-c719-46df-8a50-d94e49583e33", "result": "ENTAILMENT.\n\nThe inclusion criteria for the primary trial state that patients must have prior treatment for breast cancer with endocrine therapy (adjuvant or metastatic settings) and that this therapy should be discontinued at randomization. Therefore, all patients accepted into the primary trial have undergone prior treatment for breast cancer with endocrine therapy, which entails the statement."}
{"id": "a9907a2e-254a-45ca-af50-3e44fd2f7af3", "result": "ENTAILMENT.\n\nThe adverse event information provided in the primary trial shows that there was one case of neutropenia in both Adverse Events 1 and Adverse Events 2, which entails the statement. Therefore, the statement is true."}
{"id": "40f699a1-fbc6-40de-8e80-85b28f71632f", "result": "ENTAILMENT.\n\nThe information provided in the Results section of the primary trial states that the overall number of participants analyzed was 70, and the count of participants for each grade of adverse events was as follows: Grade 1: 53 (75.7%), Grade 2: 40 (57.1%), Grade 3: 18 (25.7%), Grade 4: 2 (2.9%), and Grade 5: 12 (17.1%). This information entails that the majority of patients in the primary trial experienced a grade 1 adverse event, and the least common severity was grade 5, which only affected 8/70 patients. Therefore, the statement is true."}
{"id": "6499b181-7a23-4073-8459-ad46ff02b20f", "result": "CONTRADICTION.\n\nThe Intervention section of the primary trial states that each treatment cycle is 28 days, and participants will be treated until disease progression. However, it does not specify the total number of cycles that participants will receive the intervention. Therefore, the statement that participants will receive the intervention for a total of 12 cycles (28 days) is not supported by the information provided in the Intervention section, and it is a contradiction."}
{"id": "2da13cd4-7189-4f85-be4d-5c1e213ae293", "result": "ENTAILMENT.\n\nThe information provided in the Adverse Events section of the primary trial states that the total number of participants who experienced non-cardiac chest pain was 2/61 (3.28%) in cohort 1. This means that less than 5% of participants in cohort 1 experienced non-cardiac chest pain, which entails the statement. Therefore, the statement is true."}
{"id": "a9bb6de9-c6f8-4c99-81cd-f101cbaab387", "result": "CONTRADICTION.\n\nThe Eligibility section of the primary trial states that patients must have radiographically confirmed metastases to the brain in order to be eligible for the trial. This means that patients without radiographically confirmed metastases to the brain are not eligible for the trial, which contradicts the statement. Therefore, the statement is false."}
{"id": "7e5fd062-6ec3-480f-ab0e-e117eba2ffe7", "result": "ENTAILMENT.\n\nThe information provided in the Results section of the primary trial states that the clinical outcome was measured using Response Evaluation Criteria In Solid Tumors (RECIST,)V1.0, and assessed by MRI or CT. The criteria for complete response, partial response, and stable disease are defined as:\n\n* Complete Response (CR): Disappearance of all target lesions\n* Partial Response (PR): >=30% decrease in the sum of the longest diameter of target lesions\n* Stable Disease (SD): a tumor that is neither growing nor shrinking\n\nThe results show that all 35 patients achieved either CR, PR, or SD, which means that they had a clinical benefit from treatment. This entails the statement that all the primary trial patients achieved either Disappearance of all target lesions, >=30% decrease in the sum of the longest diameter of target lesions or a tumor that is neither growing nor shrinking."}
{"id": "016943fa-57ea-4293-8131-03292ea1836c", "result": "ENTAILMENT.\n\nThe Eligibility section of the primary trial states that patients with operable, node-positive or high-risk node-negative HER2-positive breast carcinoma are eligible for the study. The inclusion criteria specify that patients must have no clinical or radiological evidence of metastatic disease, and must have otherwise high or intermediate risk tumor characteristics.\n\nA patient with a node-positive T2 N2 M0 adenocarcinoma of the breast would meet the criteria for high-risk node-positive tumors and would be eligible for the study.\n\nA patient with a node-negative adenocarcinoma of the breast with a tumor diameter of over 2cm would also be eligible for the study, as they would meet the criteria for high-risk node-negative tumors.\n\nTherefore, both patients would be eligible for the primary trial."}
{"id": "402f0dbf-cf67-4425-b300-a0a3df4d59d3", "result": "ENTAILMENT.\n\nThe secondary trial and the primary trial both use Objective Response (OR) as the outcome measurement for their interventions. The definition of OR is the same in both trials, referring to a patient having a best overall response of either complete response (CR) or partial response (PR), assessed according to the Response Evaluation Criteria in Solid Tumours version 1.0 (RECIST).\n\nThe primary trial measures ORR (Objective Response Rate), which is the percentage of patients with objective response, while the secondary trial measures OR, which is the number of participants with objective response.\n\nTherefore, the statement entails that the secondary trial and the primary trial use the same outcome measurement, Objective Response, to evaluate the effectiveness of their interventions."}
{"id": "62be4676-099f-4c42-8029-773af8fde6f7", "result": "CONTRADICTION.\n\nThe statement suggests that patients must be bedbound or severely disabled to participate in the primary trial, but the trial's eligibility criteria do not include such a requirement. In fact, the criteria state that patients must be able to lie still for 1.5 hours for PET scanning, which implies that they must be able to move around and be ambulatory to some extent. Additionally, the criteria do not mention anything about patients being bedbound or severely disabled. Therefore, the statement contradicts the information provided in the trial's eligibility criteria."}
{"id": "1180dd58-61b8-4c48-ab00-7d458e68c85b", "result": "CONTRADICTION.\n\nThe primary trial reports on the safety of external-beam PBI utilizing 40 Gy in ten daily fractions over two weeks, specifically looking at the incidence of grade 3 or 4 skin/subcutaneous or pulmonary toxicity, fat necrosis, and rib fractures on the ipsilateral treated side. The secondary trial, on the other hand, reports on the overall tumor response using RECIST criteria, which defines when participants improve, stay the same, or worsen during treatment.\n\nThe outcome measures reported in the two trials are not the same, as the primary trial focuses on safety outcomes while the secondary trial focuses on efficacy outcomes. Therefore, the statement that the results of the secondary trial and the primary trial report the same outcome measures entails a contradiction."}
{"id": "566bdc2d-7c4a-4547-87da-ac81447ecca8", "result": "CONTRADICTION.\n\nThe primary trial results provided in the question do not include any information about the incidence of Grade 3 or 4 skin/subcutaneous or pulmonary toxicities in either the Lapatinib Plus Capecitabine group or the Trastuzumab Plus Capecitabine group. The results only report the number of participants with Central Nervous System (CNS) metastases as the site of first relapse, and do not provide any information about adverse events or toxicities.\n\nTherefore, the statement that the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher percentage of patients with Grade 3 or 4 skin/subcutaneous or pulmonary toxicities than the Lapatinib Plus Capecitabine group is not supported by the provided information and is therefore a contradiction."}
{"id": "d310ec4e-993e-4827-8dc5-9aca053972db", "result": "ENTAILMENT.\n\nThe primary trial intervention involves Letrozole, a drug that is taken orally once daily, while the secondary trial intervention involves Sentinel Lymph Node Biopsy, a medical procedure. Therefore, the statement that the primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure entails from the given trial information."}
{"id": "a5617ae4-05a3-42d0-9e14-141de5f8c010", "result": "ENTAILMENT.\n\nThe statement \"the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial did not report any\" entails from the given trial information. The secondary trial reported 1 case of Conjunctivitis in the Adverse Events section, while the primary trial did not report any cases of Conjunctivitis in the Adverse Events section. Therefore, the statement is true and entails from the given information."}
{"id": "42d1fcd3-8faa-4065-bbba-42cc90ab67fb", "result": "ENTAILMENT.\n\nThe statement \"the secondary trial and the primary trial do not both measure the pCR of their patient cohorts\" entails from the given trial information. The primary trial measures the pCR rate as the number of patients with pathological complete response, while the secondary trial measures the disease-free survival rate. These are different endpoints and the trials do not both measure the same outcome. Therefore, the statement is true and entails from the given information."}
{"id": "d01fda83-5dc8-4ad5-92b8-7553dabd7046", "result": "ENTAILMENT.\n\nThe statement \"the outcome measurement of the primary trial is the length of time during and after the treatment, that a patient lives with the disease but it does not get worse\" entails from the given trial information. The primary trial measures progression-free survival (PFS) as the outcome measurement, which is defined as the length of time during and after the treatment that a patient lives with the disease but it does not get worse. The trial aims to evaluate the safety and efficacy of the Trastuzumab, Bevacizumab, and Docetaxel regimen in terms of PFS, and the sample size is calculated based on the expected PFS rates. Therefore, the statement is true and entails from the given information."}
{"id": "985bc5a0-bc21-447f-92f1-150e23ede3f5", "result": "CONTRADICTION.\n\nThe statement \"All the primary trial patients had a minimum of 50% decrease in the sum of the longest diameter of target lesions\" contradicts the information provided in the Results section of the primary trial. The Results section states that the clinical outcome was measured using Response Evaluation Criteria In Solid Tumors (RECIST,)V1.0, which defines a partial response as a >=30% decrease in the sum of the longest diameter of target lesions. Therefore, it is possible for patients to have a partial response with a decrease of less than 50% in the sum of the longest diameter of target lesions."}
